



Department of Forensic Medicine 
& Department of Psychiatry 
Faculty of Medicine 







ABUSE	  AND	  FATAL	  POISONINGS	  INVOLVING	  
PRESCRIPTION	  OPIOIDS	  
 























To be presented, with the permission of the Faculty of Medicine of the 
University of Helsinki, for public examination in the auditorium of Department of 








Professor Ilkka Ojanperä 
Department of Forensic Medicine 
Faculty of Medicine 
University of Helsinki, Finland 
 
Dr. Pertti Heikman, M.D, Ph.D. 
Department of Psychiatry 
Faculty of Medicine 




Professor Hannu Alho 
Department of Substance Abuse Medicine 
Faculty of Medicine 
University of Helsinki, Finland 
 
Professor Janne Backman 
Department of Clinical Pharmacology 
Faculty of Medicine 




Professor Pekka Karhunen 
Department of Forensic Medicine 
School of Medicine 





Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Universitatis 
Helsinkiensis No. 24/2015 
 
ISBN 978-951-51-0969-9 (paperback) 
ISBN 978-951-51-0970-5 (pdf) 
ISSN 2342-3161 (paperback) 
ISSN 2342-317X (pdf) 
http://ethesis.helsinki.fi 
 
Cover layout by Anita Tienhaara, photograph by Heikki Hannikainen. 
Hansaprint, Vantaa 2015 
3 
 
THESIS	  AT	  A	  GLANCE	  
Study Aim Methods Main findings 








study from 2000-2008, 
comprising 1,363 
opioid-positive cases 




Codeine and tramadol poisonings, as well 
as methadone and buprenorphine 
poisonings, were mutually similar. 
Codeine and tramadol concentrations 
were higher in fatal poisonings than in 
other deaths. Codeine, tramadol, and 
buprenorphine poisonings involved more 
additional benzodiazepines than did other 
deaths. 








study from 2000-2008, 
comprising 391 
buprenorphine-related 
cases, deceased aged 
14 to 44. 
Buprenorphine deaths were accidental 
polydrug poisonings with low drug 
concentrations. Benzodiazepines and 
alcohol were commonly associated 
findings in buprenorphine-related deaths. 
The buprenorphine/norbuprenorphine 
ratio may help in distinguishing fatal 
poisonings from other buprenorphine-
related deaths. 





profiles of the 
most common 
prescription 
opioids in Finland. 
Postmortem database 
study from 2010-2011, 
comprising 2,088 





At least 0.5% of deaths in Finland 
involved prescription opioid abuse. Every 
opioid showed certain extent of abuse 
while abuse and fatal poisonings were 
most common among men aged 20 to 49. 
Methadone and buprenorphine involved 
predominantly abuse, and abuse of 
tramadol was also prominent. 




in relation to their 
total use. 
Postmortem database 
study from 2010-2011, 
comprising 316 
pregabalin and 43 
gabapentin cases. 
 
Pregabalin showed a considerable amount 
of abuse, especially among those deceased 
aged <50. Opioids findings characterised 
gabapentinoid-abuser deaths. Pregabalin 
and gabapentin abuse may be fatal, 
especially when combined with opioids.  
V To differentiate 









data analysis study 
including 40 
consecutively 
collected samples from 
32 patients in opioid 
maintenance 
treatment. 
Positive urine buprenorphine without 
naloxone suggested use or abuse of 
buprenorphine. During maintenance 
treatment with buprenorphine-naloxone, 
all urine samples included some naloxone. 
High naloxone/buprenorphine 
concentration ratio in urine may act as an 
abuse indicator of buprenorphine-
naloxone co-formulation.  













Postmortem buprenorphine-related cases 
were assessed based on the criteria 
established in V. Many poisonings by 
parenteral buprenorphine-naloxone abuse 
were disclosed. Abuse of the co-
formulation may be even more fatal than 
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NPD nitrogen phosphorus detection 
ODT O-desmethyltramadol 
OMT opioid maintenance treatment 
ORL1 opioid-receptor-like1 
PMR postmortem redistribution of drugs 
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SNRI selective serotonin-noradrenaline-reuptake inhibitor 
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Opioids are the most important drugs causing fatal poisonings. Determining whether 
an opioid death was poisoning may, however, be difficult even if involving 
appropriate toxicological laboratory investigation. Apart from heroin, little 
statistically significant data-analysis is available for interpretation of blood 
concentrations of opioids from various types of post-mortem cases. Tolerance, route 
of administration, and delay of death after drug administration all influence 
postmortem drug concentrations. In this thesis, quantitative blood concentration data 
extracted from the high-quality Finnish postmortem toxicology database was the 
investigative tool to overcome this problem.  
Opioid deaths typically involve drug abuse, and suspected drug-abuser deaths 
must, by Finnish law, undergo medico-legal examination. Medico-legal autopsy in 
these cases includes comprehensive drug screening and, based on its results, more 
specific drug quantification. This thesis combined concentration data stored in the 
postmortem toxicology database with information from death certificates issued by 
forensic pathologists to allow statistical comparisons between drug poisonings and 
other deaths, as well as between drug abusers and other users. Concentration data 
mainly involved drug concentrations in postmortem femoral blood, but drug 
concentrations in urine and parent drug/metabolite concentration ratios also allowed 
assessment of buprenorphine, codeine, and tramadol deaths. 
Opioid poisonings proved to be mainly unintentional polydrug poisonings, 
regularly involving benzodiazepines, gabapentinoids, and other psycholeptics. 
Buprenorphine and methadone blood concentrations in fatal poisonings remained 
within their therapeutic ranges, and these two opioids involved mostly abuse. 
Concentrations of the weak opioids tramadol and codeine were above their 
therapeutic ranges both in abuser cases and in fatal poisonings. Tramadol abuse was 
common but abuse of oxycodone, fentanyl, and codeine was rather low compared to 
their therapeutic use. Abuse of the gabapentinoids pregabalin and gabapentin was 
strongly associated with opioid abuse, and compared to gabapentin abuse, 
pregabalin abuse was proportionally more frequent.   
To prevent parenteral buprenorphine abuse, opioid maintenance treatment 
applied a combination product of buprenorphine-naloxone. This combination 
product is, however, abused as well, and monitoring its abuse is challenging. In this 
study, urine samples collected from living patients at different phases of opioid 
maintenance treatment supplemented the postmortem data. Based on the criteria 
established with these patients, combined with postmortem data and proper 
background information, a urine concentration limit was estimated for suspected 
parenteral abuse of the buprenorphine-naloxone product in postmortem cases. 
Deaths and fatal poisonings due to parenteral buprenorphine-naloxone abuse 
occurred frequently, and abuse of the combination product was proportionally even 







The results of this study will assist in medico-legal cause-of-death investigations 
through providing quantitative reference concentrations for the interpretation of 
opioid-related deaths. Further, estimating the proportion attributable to prescription 
opioid abuse compared to that of other opioid use and creating abuser profiles for 
various opioids can promote public health through proper drug policy. In a clinical 
context, results may be helpful in evaluating possible drug abuse and compliance 
among prescription-drug users. Detecting abuse of these important yet addictive 





Fatal poisonings occurring annually in Finland number over 1,000, half of which are 
drug poisonings [1]. The top three drugs causing fatal poisonings in Finland are 
buprenorphine, tramadol, and codeine. These prescription opioids have, in recent 
years, taken the front positions away from tricyclic antidepressants and 
antipsychotics [1]. Antidepressant-related deaths are usually linked to suicides, 
whereas opioid fatalities involve drug abuse. Drug-abuser deaths typically include a 
combination of several drugs acting on the central nervous system (CNS). Rather 
new findings in the death statistics concern the gabapentinoids pregabalin and 
gabapentin. Along with the increases in their sales and consumption, abuse and 
deaths related to gabapentinoids seem to be increasing. Undoubtedly the increasing 
prescription drug abuse with many unintentional fatal poisonings is an undesirable 
phenomenon. 
The aging population with probably increasing pain and demand for medications 
requires caution to prevent illicit and prescription drug abuse from escalating. Drug 
abuse causes suffering to drug abusers and their next of kin, and brings disorder in 
society. Acquisition of drugs may be financed by crime. Related health problems 
from drug injection, including infections, such as hepatitis B and C and HIV, 
abscesses, cellulitis, endocarditis, or sepsis, as well as limb amputation and paresis, 
may require long, expensive hospitalization and lead to disability at work. Opioid 
maintenance treatment is efficient in treating opioid abusers and diminishing the 
harm of drug abuse, but diversion and abuse of maintenance medications also occur.  
The expanding prescription drug abuse problem is worldwide. The General 
Assembly of the United Nations has urged its member states to fight against 
prescription drug abuse, especially through informing the general public and health-
care providers [2]. According to the European Union Drugs Strategy, special effort 
should be taken to reduce drug demand and drug supply [3]. EU member states 
should invest in information, research, and monitoring of the drug-abuse situation. 
The key indicators for EU data include drug-related deaths and the prevalence and 
pattern of problem-drug use in the general population, the topics this thesis aims to 
cover. 
Published postmortem toxicology studies are often based on only a few cases, 
but medico-legal cause-of-death investigation should not merely rely on case reports 
[4]. Forensic case reports are useful in discovering new trends, but proper statistical 
analysis and generalizations require larger, comprehensive data sets. The Finnish 
postmortem toxicology database provides quantitative data with representative 
population-based results based on actual laboratory measurements and routine 
screening of several hundred different drug compounds.  
This thesis focuses on exploring laboratory results stored in this extensive 
postmortem toxicology database, completed with information from cause-of-death 
investigation issued in referrals and death certificates by forensic pathologists. This 
thesis aims at developing methods for distinguishing opioid and gabapentinoid 
poisonings from other deaths related to these drugs, at determining abuser profiles of 
prescription opioids to provide better understanding of drug abuse for medico-legal 




REVIEW	  OF	  THE	  LITERATURE	  
1	  Opioids	  
1.1 Basic	  pharmacology	  
Opioids are psychoactive substances whose pharmacological effects resemble those 
of morphine or other opiates. Opiates are natural alkaloids of the opium poppy 
(Papaver somniferum), and the term “opioid” refers to opiates, synthetic derivatives 
of the opium poppy, and endogenous opioid peptides produced naturally in the body, 
such as endorphins, enkephalins, dynorphins, and endomorphins. Morphine and 
codeine are opiates, oxycodone and buprenorphine are semisynthetic opioids, and 
tramadol, fentanyl, and methadone are synthetic opioids. Commonly, the term 
“opiate” is associated with compounds that test positive in the opiate immunoassay, 
such as morphine, codeine, heroin, and the heroin metabolite 6-
monoacetylmorphine.  
Opioids bind to opioid receptors, the main classes of which are µ (mu), κ 
(kappa), δ (delta), and ORL1 (opioid-receptor-like1) receptors. Opioid receptor µ 
mediates, among others, analgesia, respiratory depression, euphoria, and physical 
dependence. Receptor κ mediates analgesia, especially in the spinal cord, and 
sedation and dysphoria. Receptor δ mediates analgesia, especially in peripheral 
tissues. The ORL1 receptor is important in pain responses and development of 
tolerance to µ agonists. Each opioid has a unique binding affinity to opioid 
receptors, which leads to different profiles of its opioid effects.  These effects 
include analgesia, sedation, euphoria, respiratory depression, miosis, and nausea. In 
a medicinal context, opioids are useful against pain and cough, and in opioid 
maintenance treatment (OMT) for opioid-dependent patients.  
Table 1 summarizes the pharmacokinetics of opioids and some other drugs. 
Codeine is a weak opioid against pain and cough. Codeine is mainly metabolized via 
cytochrome P450 (CYP) 2D6 to its major metabolite morphine.  
Tramadol is a weak opioid derivative of codeine. The analgesic effects of 
tramadol are based on both opioid µ receptor and serotonin and noradrenalin 
reuptake inhibition. The main active metabolite is O-desmethyltramadol (ODT), 
which is formed by CYP2D6. Tramadol itself has low affinity to opioid receptors, 
but O-desmethyltramadol has significant opioid receptor affinity. Polymorphism of 
CYP2D6 activity and other CYP2D6-metabolizing medications may influence 
tramadol’s effects: reduced CYP2D6 activity produces less O-desmethyltramadol, 
which reduces its analgesic effects. Tramadol, as well as other weak opioids, has a 
ceiling effect: at high dosing, the analgesic effects cease to increase. The 
concentrations of tramadol and O-desmethyltramadol peak at different times in the 
brain, and a larger dose of tramadol does not lead to a correspondingly increased 
amount of O-desmethyltramadol in the brain [5]. At higher doses, tramadol also 
lowers seizure threshold by increased serotonin-receptor inhibition [5].  
Buprenorphine serves as an analgesic and in OMT. It has a rather complex 
pharmacology, characterized as a partial µ receptor agonist, a κ and δ receptor 
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antagonist, and a weak partial agonist of ORL1. In Finland, buprenorphine is usually 
classified as a medium-strength opioid.  
Fentanyl is a potent agonist for receptor µ, 100 times more potent than morphine. 
Fentanyl can be used as anesthetic or in rapid pain relief by an intravenous route, as 
well as against chronic pain with transdermal patches. Fentanyl has rapid onset and a 
short duration of action (Table 1). Its administration route is most commonly 
transdermal, transmucosal, or intravenous.  
Oxycodone is a strong opioid against severe pain, primarily metabolized via 
CYP3A4 and CYP2D6 to several metabolites, such as the active metabolite 
oxymorphone and the relatively inactive noroxycodone. Compared to morphine, 
oxycodone has higher oral bioavailability, faster onset of action, and longer duration 
of action, but unlike morphine, oxycodone is prone to drug-drug interactions due to 
its CYP-mediated metabolism [6].  
Methadone is used against pain and in OMT, acting as an agonist for receptor µ 
and an antagonist for receptor NMDA (N-methyl-D-aspartate). As medication, 
methadone is available as a rasemic mixture of 50% levomethadone (L-methadone) 
and 50% dextromethadone (D-methadone). L-methadone acts via the µ-receptor and 
D-methadone via the NMDA receptor.  Via effects on the NMDA receptor, 
methadone somewhat reduces neuropathic pain and reduces and reverses opioid 
tolerance. Absorption, bioavailability, clearance, and elimination of methadone 
show extreme inter-individual variation [7]. The main metabolite, produced via 
CYP3A4, is pharmacologically inactive EDDP (2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine). Methadone accumulates in tissues, which act as a methadone 
supply, leading to higher and steadier concentrations in tissues than in blood.  
Naloxone is injected to treat acute opioid poisoning, and in sublingual 
buprenorphine-naloxone combination products, it diminishes intravenous 
buprenorphine abuse. Naloxone is a semisynthetic opioid, but it is a full receptor µ, 
κ, and δ antagonist.  It has extensive first-pass metabolism, leading to its 
insignificant effect when administered orally. The full opioid µ and δ receptor-
antagonist naltrexone can be administered orally and sometimes serves in treating 
opioid dependency for highly motivated persons after withdrawal to prevent further 
opioid use, and in treating alcohol dependence. Orally administered nalmefene is a µ 
and δ antagonist and a partial κ agonist that has been introduced to reduce alcohol 





Table 1. The basic pharmacokinetics of the opioids studied, gabapentinoids, and 
some benzodiazepines [9]. 
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2 2.6-2.8  metabolism  46 0.5-1.3 
Pregabalin 90 [11] 0.5-0.6  renal 
excretion 
  0 5-11 
Gabapentin 27-60 0.8-1.3  renal 
excretion 
none <3 5-9 
Alprazolam 88 0.9-1.3 metabolism α-hydroxy- 
alprazolam 
65-75 6-27 









Temazepam  0.8-1.0 metabolism oxazepam 97 3-13 
 
Vd volume of distribution 	  







Buprenorphine maintenance treatment for opioid addicts has proven successful in 
many reports, and buprenorphine is now an effective alternative to methadone 
internationally [12]. Buprenorphine undergoes extensive first-pass metabolism and 
therefore has low oral bioavailability. Its biovailability by the sublingual route has 
been estimated as 51.4% and by the buccal route as 27.8%, although both 
administration routes involved considerable inter-individual variability [10]. The 
mean time to maximum plasma concentration following sublingual administration is 
variable, ranging from 40 minutes to 3.5 hours [13]. Buprenorphine has a large 
volume of distribution (Vd) and is highly protein bound (96%) [13]. A low 
correlation (r2=0.261) existed between its mean dose and mean plasma concentration 
in a study with 17 buprenorphine cases on a  maximum daily dose of 8 mg [14]. 
Buprenorphine is metabolized to an active metabolite norbuprenorphine and the 
respective glucuronide conjugates [15,16]. Norbuprenorphine has an estimated one-
fiftieth the analgesic potency of buprenorphine [17]. The N-dealkylation to 
norbuprenorphine is primarily mediated by CYP3A4 [18]. A considerable variation 
occurs in reported values of the terminal elimination half-life of buprenorphine, with 
mean values ranging from 3 to 44 hours [13]. In parenteral administration, its half 
life is much shorter than by the sublingual route (Table 1). Most of each 
buprenorphine dose is eliminated as metabolites in the feces, with approximately 10 
to 30% excreted in urine [13].  
A plateau in buprenorphine opioid effects is consistent with its partial agonist 
classification, and the fact that nondependent human beings tolerate well single 
doses of buprenorphine up to 70 times the recommended analgesic dose [19]. A 
ceiling on the effects of buprenorphine in humans may reduce its abuse liability and 
improve its safety, and indicate that opioid blockade occurs after acute 
buprenorphine administration [20]. Buprenorphine appears to have a ceiling for 
cardiorespiratory and subjective effects and a high safety margin even when taken 
intravenously [21].  
In the pioneering country France, all general practitioners have been permitted to 
prescribe buprenorphine without special training or licensing since 1995. In France, 
intravenous diversion of buprenorphine has led to relatively rare overdosing in 
combination with sedatives, whereas illegal opioid overdose deaths declined 
substantially [22]. Reports from the United States indicate that the prescription of 
buprenorphine for opioid-dependence treatment can be incorporated into primary 
care practice, and many patients, including polysubstance users, thereby benefit 
[23].  
In Finland, buprenorphine has been on the market since 1981, first as a pain 
medication. As early as 1985-1990, one general practitioner in Helsinki used 
buprenorphine in the treatment of opioid addicts with questionable results. In 1995, 
he developed the Benedictus treatment; the regimen included a visit to the doctor, a 
support person and treatment with buprenorphine [24]. The treatment typically 
included a benzodiazepine, most often temazepam [24]. The number of patients 
escalated and finally this doctor lost control and was found guilty of smuggling and 
selling buprenorphine tablets, and lost his license [25]. This history may have 
influenced the Finnish drug scene with its frequent intravenous use of 
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buprenorphine, whereas the supply of heroin is scarce [26,27]. It was not until 2000 
that buprenorphine became legal in withdrawal and maintenance treatment of 
opioid-dependent patients. At first, Finnish opioid addicts mainly obtained their 
buprenorphine from French general practiotioners [28]. Later, restriction of 
treatment became less strict, and at present, primary health care units are allowed to 
administer buprenorphine treatment.  
Concern about intravenous buprenorphine abuse in Finland arose shortly after 
those buprenorphine treatments began [28]. The opioid antagonist naloxone has been 
added to a sublingual formulation of buprenorphine to reduce its intravenous abuse 
liability. This approach is based on the fact that the sublingual bioavailability of 
naloxone is only approximately 10% and elimination half-life 1 to 2 hours [29]. A 
buprenoprhine-naloxone combination product (BNX) came into use in New Zealand 
in 1991, and concern as to its intravenous abuse rose shortly after [30]. In Finland, 
BNX has been available in OMT since 2004, and since 2008, designated pharmacies 
can deliver BNX under certain preconditions. Many studies have confirmed the 
abuse liability of BNX in Finland [31,32] and elsewhere in the world [33-35], but 
the actual substantial proportion of BNX abuse among fatal buprenorphine 
poisonings remained unknown until the results of Study VI. 
In OMT, many have attempted to prevent intravenous BNX abuse. Crushing 
soluble buprenorphine tablets does not reduce their clinical effects, but such 
crushing may reduce their diversion [36]. No studies exist on crushing the sublingual 
BNX co-formulation. One option for soluble tablets is a soluble BNX film. In 
reducing diversion and abuse, however, BNX film seems not to be superior to other 
BNX formulations: diversion and clinical outcomes of the BNX film have been 
similar to those for BNX tablets [37-39]. In Finland, BNX film use started in 
summer 2014 in some treatment units with special permission, but thus far, longer 
Finnish experience with BNX film is still lacking. Crushed BNX tablets and BNX 
film may be alternatives when OMT medications are taken daily at a clinic, but as 
take-home doses, these may contribute to abuse as frequently as do other 
formulations. Electronic medicine dispensers may prevent some OMT patients from 
diverting their take-home doses, but these had no effect on the availability or price 
of illegal BNX [40]. Subdermal buprenorphine implants providing low 
buprenorphine levels for six months have been effective compared to placebo 
implants [41,42] and were not inferior to sublingual BNX [42], but additional 
studies on their safety and efficacy are necessary until they are approved for 
treatment. 
2	  Gabapentinoids	  
2.1	  Therapeutic	  use	  and	  abuse	  
Pregabalin and gabapentin are GABA (gamma-aminobutyric acid) analogues which 
bind to the α2δ (alpha-2-delta) subunit of the voltage-dependent calcium channel in 
the CNS. They have no activity through binding to GABAA receptors, but in the 
brain they lead to increased GABA synthesis. GABA is the brain’s most important 
inhibitory neurotransmitter; increases in GABA reduce release of excitative 
neurotransmitters. Although rather similar medications, pregabalin and gabapentin 
do exhibit some differences. Unlike that of pregabalin, absorption of gabapentin is 
saturable, which means that with larger doses some of the gabapentin remains 
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unabsorbed; the daily dose of gabapentin should be divided into three portions, 
whereas pregabalin can be administered twice a day [11]. The dose-response 
relationship of pregabalin is steeper than that of gabapentin [11].  
Gabapentinoids are effective in treating chronic neuropathic pain such as 
postherpetic neuralgia and diabetic neuropathy [43], and pregabalin is also effective 
against fibromyalgia [43,44]. Pregabalin is somewhat more effective for postherpetic 
neuralgia and epilepsy [11]. In Europe, pregabalin is approved for generalized 
anxiety disorder (GAD).  In long-term treatment of GAD, pregabalin has been 
suggested as a first-line drug along with selective serotonin-reuptake inhibitors 
(SSRIs) and serotonin-noradrenaline-reuptake inhibitors (SNRIs) [45].  Pregabalin 
has been somewhat effective, as well, in treating restless legs syndrome [46]. It has 
shown some beneficial effects in alcohol relapse prevention, especially in patients 
with comorbid conditions such as alcoholism and GAD, but its efficacy for alcohol-
withdrawal syndrome remains controversial [47]. Pregabalin use in off-label 
indications other than fibromyalgia or restless legs syndrome is discouraged due to 
its lack of effect in clinical studies and its risk of abuse [48]. Although 
gabapentinoids belong to the group of first-line medications against neuropathic 
pain, so do some antidepressants and other medications [49], and other options for 
their various indications are available. 
Pregabalin has been on the market in Finland since 2004. Signs of pregabalin 
abuse emerged in 2007, based on postmortem data, when deaths caused by 
pregabalin rose from 1 to 7 per annum [50,51]. In 2010, fatal pregabalin poisonings 
in Finland numbered 15, making pregabalin the eleventh most common cause of 
fatal poisonings [1].  Pregabalin abusers typically use concomitant benzodiazepines, 
opioids, and alcohol [50].  The administration route in abuse cases is usually oral, 
but intravenous abuse also occurs [50]. Although the abuse potential of pregabalin 
was by then known, the frequency of pregabalin abuse in Finland was unclear until 
publication of Study IV.  
2.2	  Concomitant	  gabapentinoid	  and	  opioid	  use	  	  
Both opioids and gabapentinoids are medications against pain, but their indications 
vary. As pain medications, gabapentinoids are indicated for neuropathic pain, and 
opioids for nociceptive pain. In severe pain conditions, pregabalin and opioids can 
be co-administered [49,52-54]. Pregabalin and oxycodone combination therapy 
against neuropathic pain results in a dose-reduction in both drugs and a superior 
safety profile compared with that of pregabalin monotherapy [52]. In clinical studies 
involving diabetic neuropathy and postherpetic neuralgia, gabapentinoid 
combination therapy with opioids has shown mainly positive responses [53]. 
Whereas gabapentinoids, among some other drugs, are the first-line medications for 
various neuropathic pain conditions, strong opioids are recommended as second- or 
third-line choices because of the potential risk of abuse in long-term use [49]. The 
European Federation for Neurological Societies recommends, for patients showing 
only a partial response to these drugs administered alone, a combination therapy of 
gabapentin combined with opioids or tricyclic antidepressants [49].  
Gabapentinoids combined with opioids may also involve abuse. Abuse of 
pregabalin is increasing, especially among opioid-dependent individuals [55,56]. 
Abuse of gabapentinoids to get high has recently been reported among patients on 
both methadone [57] and buprenorphine medication [58]. The substantial proportion 
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of pregabalin abuse among opioid-related fatalities, however, remained undefined 
until the results of this thesis study. 
3	  Benzodiazepines	  
3.1	  Therapeutic	  use	  and	  abuse	  
Benzodiazepines are psychoactive substances effective for anxiety, insomnia, 
agitation, muscle spasms, seizures, and alcohol withdrawal, and as premedication for 
medical procedures. Benzodiazepines bind to the GABA-benzodiazepine receptor 
complex in the CNS. Their primary target is the GABAA receptor, a chloride 
channel activated by GABA. Benzodiazepines reinforce the inhibitory effects of 
GABA, leading to decreased excitability of neurons and a calming effect on brain 
functions. Benzodiazepines differ from each other in physiochemical properties such 
as lipid solubility and rate of absorption and diffusion. Many benzodiazepines 
involve CYP metabolism, which is a potential pharmacokinetic mechanism resulting 
in drug-drug interactions with other drugs. 
Benzodiazepine findings are especially challenging to interpret because of their 
common metabolic pathways (Table 1). Diazepam is metabolized to the active 
metabolites nordazepam and temazepam, which are further metabolized to 
oxazepam. Temazepam and oxazepam are both also parent drugs produced and sold 
as such. This makes it difficult to know what product the deceased had taken in the 
usual situation of scarce background information. Differentiating parent drugs from 
metabolites is important when studying what product or how many different 
benzodiazepines a victim has consumed, and when interpreting the concentration 
results.  In the literature, this problem of exactly which compounds have been 
consumed is usually neglected. Diazepam and oxazepam concentrations, for 
example, may be given as such and both be regarded as parent drugs, without 
dividing them into metabolites and parent drugs [59].  
Benzodiazepines are the most abused and addictive group of medications in 
Finland [60]. Some researchers have suggested that they should not be prescribed to 
anyone drug-addicted because of the abuse risk [61]. Benzodiazepine abuse is 
usually oral with large doses, but intravenous abuse also occurs [60]. Concomitant 
use of other drugs among benzodiazepine abusers is highly common.  
Because prescribing benzodiazepines always includes the risk for abuse, 
diversion, and addiction, the Finnish National Supervisory Authority for Welfare 
and Health (Valvira) has created instructions for prescribing benzodiazepines. These 
instructions state that benzodiazepine treatment should be short, usually a maximum 
of 4 to 12 weeks, including the gradual termination of treatment [62]. Besides 
benzodiazepines, many conditions can and should be treated with other, more 
suitable and less addictive medications [62]. Most patients prescribed 
benzodiazepines will not become dependent, but because the number of 
benzodiazepine users is large, the problem of abuse and dependence is considerable 
[62]. The Hospital District of Helsinki and Uusimaa (HUS) has also created 
instructions, ones based on those initiated by Valvira. These instructions point out 
that short-acting benzodiazepines such as lorazepam, alprazolam, triazolam, and 
midazolam should be avoided because of the abuse risk. Diazepam 10-mg tablets 
and temazepam should be avoided because of their desirability among drug abusers. 
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Prescription of the first benzodiazepine or other potentially addictive medication 
should depend on careful consideration [62]. 
Recreational abuse of one benzodiazepine, phenazepam, emerged in 2010 in 
Europe and the United States [63,64]. Phenazepam is available in Russia for 
sleeping disorders, epilepsy, and alcohol withdrawal. Although it is not available as 
a medicinal product in Finland, phenazepam’s abuse has been a widespread 
phenomenon also in Finland [63]. The Finnish Medicines Agency (Fimea) classified 
phenazepam as a narcotic in Finland in May 2014.  
3.2	  Concomitant	  opioid	  and	  benzodiazepine	  use	  
OMT clients are particularly vulnerable to concomitant opioid and benzodiazepine 
use and may try to potentiate the effects of opioids with benzodiazepines [65]. 
Among opioid users, drugs not depressing the CNS, or non-pharmacological 
treatments should be the preferrence over benzodiazepines [65]. Opioid-dependent 
subjects in buprenorphine maintenance treatment who also have benzodiazepine 
dependency or abuse experience a poorer outcome in life than do patients without 
problematic benzodiazepine use or patients using no benzodiazepines [66]. Some 
opioid addicts seem to use benzodiazepines as a self-medication for psychiatric 
comorbidities or to counter negative affect [67]. Self-medicating with 
benzodiazepines may appear in OMT with an inadequate dose of OMT medication 
[68]. Benzodiazepine prescriptions in buprenorphine maintenance treatment are 
associated with increasing accidental injuries, but not with outcomes of opioid 
treatment [69]. 
Although benzodiazepines and opioids are metabolized by CYP enzymes, 
pharmacokinetic interactions between them seem mostly clinically irrelevant 
[65,70]. Interactions between benzodiazepines and opioids seem mainly 
pharmacodynamic and can result in potentiated respiratory and other CNS 
depression [70].  
After publication of Studies I and II, other studies have also confirmed the 
frequency of combined opioid and benzodiazepine abuse and its consequences. 
Benzodiazepines are common findings in opioid-related fatalities [71]. 
Benzodiazepines have a wide safety margin when consumed alone, without other 
CNS depressants, which may lead to underestimation of their dangerous nature 
when combined with opioids [71]. The combination of methadone and 
benzodiazepines may be more dangerous than the combination of buprenorphine and 
benzodiazepines, because the former have led to higher hospitalization rates and 
worse medical outcomes [72]. Among chronic pain patients on long-term opioid 
treatment, concomitant opioid and benzodiazepine consumption is common, as is 




4	  Drug	  poisonings	  
4.1	  Fatal	  poisonings	  in	  Finland	  
In Finland, fatal poisonings number annually 1,000 to 1,200 (Figure 1). Of all the 
fatal poisonings, alcohol and drugs each contributes to 40 to 50%; poisonings other 
than those alcohol- and drug-related mainly result from carbon monoxide. Fatal 
poisonings have generally declined, but an increase is evident in poisonings related 
to drug abuse, including both illicit substances and abused prescription medications. 
In 2010, fatal opioid poisonings numbered 189, being the most important drug group 
causing fatalities. Opioid poisonings involved buprenorphine, tramadol, codeine, 
fentanyl, methadone, and oxycodone, and only two cases of heroin. In second place 







Figure 1. Fatal poisonings in Finland from 2000 to 2010, based on data from Vuori 


























4.2	  Opioid	  poisonings	  
Non-fatal opioid overdoses in Finland peaked in the year 2000 and declined rapidly 
thereafter [76]. Back then, the chief abused opioid was heroin, but buprenorphine 
has since replaced it, also in non-fatal overdoses [76]. The number of non-fatal 
buprenorphine poisonings was then lower than was the number of heroin poisonings. 
Polydrug use more often involved non-fatal buprenorphine overdoses, but severe 
respiratory depression was rarer among buprenorphine than among heroin overdoses 
[76].  
Opioid poisonings are quite straightforward and easy to treat in hospitals, but the 
difficulty lies in the fact that potentially fatal opioid poisonings usually occur 
outside hospitals; most often the deceased are found dead. Opioid poisonings in this 
study refer to deaths occurring after opioid overdose, as overdose is, among opioid 
dependents, their most common cause of death [77,78]. A classic pattern of an 
opioid poisoning involves a long-time drug abuser: an opioid-addicted man in his 
thirties, who is found dead outside a hospital with a syringe and empty packages of 
opioids and other medications [79-85]. Injecting as the primary route of 
administration increases the risk of premature death [77,79]. Polydrug toxicity is the 
major factor causing opioid poisonings, whereas drug impurities or variations in 
illicit drug purity are practically insignificant [84,85].  
The main mechanism of fatal opioid poisoning is respiratory depression. 
Tolerance to respiratory depression is relatively slow and incomplete compared to 
tolerance to the euphoric effects of opioids [86]. Risk for overdose is greater after 
abstinence, because the dose previously necessary for euphoric effects can cause 
respiratory depression due to diminished tolerance. Benzodiazepines and alcohol are 
dangerous when used concomitantly with opioids, because they all inhibit CNS via 
acting on the GABAA receptor. In these polydrug cases, naloxone may be 
insufficient, because naloxone inverts only that respiratory depression due to the 
opioid, without affecting the consequences of other compounds [86]. According to 
studies with forensic case series, a typical mechanism of death in opioid poisoning is 
prolonged asphyxia including cyanosis, pulmonary edema, and multivisceral 
congestion [79,80,87,88].  
5	  Postmortem	  toxicology	  data	  
5.1	  Postmortem	  studies	  
Postmortem toxicology data are based on measured drug concentrations in autopsied 
bodies. Analyses provide information on multiple drug findings and new trends in 
drug abuse. In postmortem toxicology, no prior information on drugs taken is 
necessary because broad-spectrum drug screening methods are generally applied. 
Postmortem blood concentrations, usually measured in whole blood, may, however, 
differ from therapeutic reference drug concentrations measured in living persons. A 
therapeutic reference concentration is for many drugs measured for plasma, although 
some medications, such as cyclosporin and tacrolimus, are redistributed into the 
erythrocytes, and their concentrations are measured in whole blood even among 
living patients. For opioids, the postmortem blood/therapeutic plasma concentration 
ratio is 1, suggesting that in a comprehensive postmortem data set, median 
postmortem concentration is within the established therapeutic range for plasma 
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[89]. For gabapentin, this ratio was 1.8, and for pregabalin, 1.6, suggesting that 
median postmortem concentrations of gabapentinoids are above the therapeutic 
range divided by the upper limit of the therapeutic range; this is likely due to 
postmortem redistribution of drugs (PMR) [89]. This suggests that postmortem 
concentrations of gabapentinoids might be somewhat higher than they are 
antemortem.  
Published postmortem toxicology database studies typically include only cases in 
which an opioid or another substance was the cause of death or at least a 
contributory factor on a death certificate [90,91]. Especially if the studies are based 
on general registers, not all drugs are taken into account, and the studies may 
underestimate the total number of drug findings. In polydrug poisonings, the 
individual substance that is the most important cause of death may remain unclear. 
In Finnish postmortem data, when compared to the whole population, drug abusers 
are overrepresented. Consequently, postmortem results provide good estimates, 
especially for young abusers [92]. 
 
5.2	  Postmortem	  drug	  concentrations	  
Postmortem blood drug concentrations should be measured in femoral venous blood 
because of PMR. Due to PMR, postmortem concentrations among tissues vary. 
Reasons for this include differences in postmortem drug release from different 
organs, such as the gastrointestinal tract, lungs, myocardium, and liver, from 
putrefaction, blood movement, coagulation, hypostasis, and drugs’ pharmacokinetic 
and chemical properties, such as acidity, lipophilicity, binding to proteins, high Vd, 
or residual metabolic activity [93]. PMR is relevant especially for drugs with a high 
Vd [94]. Vd is the theoretical volume which defines the distribution of a medication 
between plasma and the rest of the body. The higher the Vd, the more of the drug 
will be distributed in the tissues than in plasma. Among opioids, methadone has the 
greatest Vd (Table 1), indicating more accumulation in the body. When the 
distribution is not uniform, after death the distribution will possibly become more 
uniform because of stabilization of the concentration gradient [94].  
Peripheral samples from femoral blood are the least subject to PMR and should 
generally be the choice for concentration measurements [93,95,96]. Some PMR 
occurs also in femoral blood. Some evidence suggests that postmortem 
concentrations of morphine and codeine [97], and of fentanyl [98], especially in 
fentanyl-abuse cases [96,99], may be higher than their respective antemortem 
concentrations. These small differences are, however, probably insignificant in the 
interpretation of toxicological findings in death cases. For example, median 
peripheral blood concentrations for codeine at mortuary admission was 0.108 mg/l, 
and at autopsy, 0.114 mg/l [100]. These figures were, respectively, for methadone 
0.377 and 0.448 mg/l, for morphine 0.262 and 0.253 mg/l, for oxycodone 0.141 and 
0.142 mg/l, and for tramadol 1.531 and 1.045 mg/l [100]. The difference was 
statistically significant only for methadone [100], but both of the methadone median 
concentrations were well within therapeutic range. 
In blood circulation, drugs are dissolved in plasma, bound to plasma proteins or 
bound to membranes, or contained in the erythrocyte cytoplasm [93]. Plasma 
proteins can act as a reservoir of any circulating, inactive drug. After death, blood 
proteins such as albumin leak out of the bloodstream into tissues, leading to reduced 
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concentration of albumin-bound drugs in the blood [94]. High postmortem drug 
concentrations can sometimes result from transfer across previously impermeable 
body barriers, such as resulting from absorption through the gastrointestinal tract, 
lungs, liver, myocardium, or urinary bladder [93,94]. Blood drug concentrations may 
then be higher near organs in which that drug is normally concentrated, and drug 
concentrations measured in blood may depend on the sample site [94]. This may be 
important in traumas that damage internal organs, especially organs near femoral 
veins, from which blood samples usually are collected. The time-interval between 
death and sample collection may affect postmortem drug concentrations. The 
opioids and gabapentinoids studied here are, however, rather stable in plasma and 
urine [9]. During body putrefaction, bacteria and microorganisms can synthesize 
ethanol and metabolize certain drugs such as benzodiazepines [93].  
Drug concentrations may become higher or lower than expected due to drug-
drug interactions such as inhibition or induction of drug metabolism. Opioid 
metabolism involves, for example, several CYP isoforms. Codeine is a substrate for 
CYP2D6, an enzyme whose activity is extremely variable due to genetic 
polymorphisms. The ultrarapid-metabolizer phenotype of CYP2D6, due to gene 
duplication, can lead to high morphine concentrations after only a low dose of 
codeine, whereas poor metabolizers lacking CYP2D6 activity produce virtually no 
morphine [101,102]. Tramadol’s analgesic effects, side-effects and risk for 
poisoning increase among ultrarapid CYP2D6 metabolizers due to increased O-
desmethyltramadol formation [103].  The clinical significance of genetic CYP2D6 
polymorphism in the analgesic effect of oxycodone is controversial, although the 
active metabolite oxymorphone is produced by CYP2D6 [6].  Because oxycodone is 
mainly metabolized by CYP3A4, inhibition of CYP3A4 leads to increased exposure 
to oxycodone [6]. High postmortem methadone concentrations occur in slow 
metabolizers of CYP2B6 [104]. Even those with normal CYP activity may become 
temporarily poor metabolizers when taking concomitantly CYP-inhibiting 
medications, such as when a codeine user takes the concomitant CYP2D6-inhibitors 
fluoxetine, paroxetine, or terbinafin. Unlike for opioids, metabolism of the renally-
excreted pregabalin and gabapentin in humans is negligible, but pharmacodynamic 
CNS depression by other drugs can lead to increased gabapentinoid toxicity [11]. 
When opioids are administered regularly, tolerance increases. Tolerance may be 
one reason for overlapping antemortem concentrations among regular drug users, 
such as drugged drivers, and postmortem concentrations [105,106].  In non-fatal 
pregabalin poisonings, as well, concentrations may be considerably higher than the 
drug’s therapeutic ranges [107,108]. Loss of tolerance may play a significant role in 
the deaths of those drug abusers who have undergone some period of abstinence, 
such as after their release from prison or shortly after detoxification treatment [84].  
In parenteral administration, such as intravenous injections or intranasal snorting, 
drug doses may be lower than when administered orally, because, for many opioids, 
intravenous administration leads to a rapid onset of action and full bioavailability. 
Consequently, postmortem concentrations of intravenously abused drugs may be 
within therapeutic ranges even in fatal drug poisonings [81,82]. Those dead from 
opioids usually show signs of prolonged asphyxia, and particularly buprenorphine 
poisonings may be delayed: the deceased dies of prolonged respiratory depression 
while asleep [81,87]. Then the postmortem concentrations will be lower than are 
drug peak concentrations after drug administration. Drug concentrations alone can 
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rarely determine the manner of death; case histories should always receive close 
scrutiny [94,98]. 
6	  Toxicological	  drug	  screening	  
In postmortem toxicology, drug screening aims to reveal all the relevant drugs the 
deceased had used recently. In blood, drugs are mainly present as the parent 
compounds, except for prodrugs, which are present as active metabolites. Urine 
samples include drug metabolites. The time-scale for drug detection depends on the 
specimen screened. Blood concentrations reveal the influence of drugs at the time of 
death. Urine concentrations reveal drug use after a longer period, usually within a 
few days following drug consumption, even when the clinical drug effects have 
already vanished. Other possible matrices in postmortem toxicology include, for 
example, vitreous humor, hair, muscle, liver, fat, lung, bone, and even the larvae 
found in putrefying bodies [109]. These matrices are primarily utilized in qualitative 
drug analyses to reveal drugs the deceased had consumed, or their metabolites. 
Factors affecting drug concentrations and findings in postmortem data mostly 
involve PMR, putrefied samples, contamination with tissue fluids, and drug 
decomposition [94,109]. 
Among living patients, drug screening provides information on patient 
compliance. Blood, serum, or plasma samples provide information on dosing and 
poisonings. Methadone metabolism has great inter-individual variability, and 
measuring methadone serum concentrations of OMT patients helps in adjusting for 
the proper dose. In suspected poisonings, drug concentrations measured in blood 
samples allow specific diagnostics and treatment. Urine is a useful screening matrix 
in revealing inappropriate substance use, such as illegal drug use in OMT. Other 
possible screening matrices in the clinical setting include oral fluid, hair, and sweat 
[110]. In routine urine screening among living patients, the first test is traditionally a 
qualitative immunoassay-based test indicating a substance’s presence or absence. 
Prevalence of both false positives and false negatives in these immunoassay-based 
screening tests is rather high, and the results need confirmation by reliable mass-
spectrometry-based methods, at least in cases where sanctions or judicial 
consequences may follow a drug-positive test result. In research and compliance 
monitoring, developing and applying sufficiently accurate laboratory methods for 
drug screening is vital. Prior to the results of Study V, as tested among BNX 
maintenance patients, typical urine naloxone concentrations after sublingual 
administration of BNX were unclear. 
Urinary parent/metabolite ratios may be helpful in monitoring compliance, 
because patients may try to adulterate their samples. Urine-sample adulteration may 
include, for example, dilution, substitution, or addition of substances to the sample. 
A drug-abusing patient in methadone maintenance treatment may, for example, add 
liquid methadone to a urine sample bought from someone using no medications, in 
order to produce a sample demonstrating only the prescribed methadone. In routine 
immunoassay-based presence- or absence-screening, this adulteration may be 
impossible to detect, but quantitative confirmation analysis can prove adulteration.  
EDDP can serve as a marker of compliance among patients in long-term methadone 
treatment: a high concentration of methadone combined with no EDDP suggests 
sample adulteration [111]. Another approach in compliance monitoring can be 
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quantitative measuring of the urine EDDP/creatinine ratio, which may predict the 
dose of methadone consumed [112]. 
7	  Substance	  abuse	  
7.1	  Definition	  of	  drug	  abuse	  
Drug misuse typically refers to substance use not appropriate for medical indications 
or not matching prescribed dosing [113]. Drug misuse involves, for example, too-
large or too-small dosing, and it may be wilful or unintentional. Drug abuse means 
that the substance is used for nontherapeutic purposes, usually to obtain 
psychotropic effects such as euphoria, sedation, or to cause anxiolytic effects [113]. 
Some definitions of drug abuse also include contradiction of medical advice, taking 
medication against prescription, drug use causing harm to the user, or illegal 
substance use [113]. In the present work, drug abuse means, consistently with these 
definitions, intentional recreational substance use as narcotics. 
7.2	  Methodological	  approaches	  
Different approaches are available for studying substance abuse and its properties 
and prevalence. Animal studies help us to discover drug properties and toxicity 
[114,115] as well as some abuse potential [116]. Case reports usually give the first 
insights into possible abuse problems [117], to be followed by longer case series 
reports [80-83]. Traditional surveys concerning drug abuse include questionnaires 
and population surveys [118-120], or surveys in addiction clinics [121], or needle-
exchange programs [32]. Adverse drug reaction and pharmacovigilance database 
surveys may provide indications of drug dependency or addiction [122]. Calls to 
poison centers provide information on trends in emerging drug toxicity, overdoses, 
and abuse [123]. Seizures by Customs reveal trends in drug supply and new 
recreational substances [124]. Studies on apprehended drivers provide information 
on the range of medications used and abused as well as their concentrations related 
to psychomotor performance [63,105,106,125]. Finally, therapeutic drug monitoring 
produces data on the clinically relevant drug concentrations of certain drugs in 
plasma, serum, or whole blood. 
Substance abusers participate poorly in population-based studies such as 
questionnaires or interviews, and they may underreport their drug use. It is also 
possible that the substances they take may have remained unknown even to 
themselves. Another type of study has been conducted to overcome the problem of 
scarce participation. Patterns of drug abuse in local communities have been 
monitored by wastewater analysis, which means detecting drugs and metabolites in 
communal sewage water [126,127]. Social media has nowadays a profound impact 
on public health, and studies of Twitter comments have provided real-time 
epidemiology of the drug-abuse scene [128,129]. Anecdotal internet reports have 
provided information on relatively new psychoactive substances and their abuse 
potential. An increase in the online drug debate typically precedes clinical drug 
abuse events at population level [130,131]. Computer models have predicted what 
types of individuals become opioid abusers or dependent on opioids. Those more 
likely to develop opioid abuse or dependency are, for example, male, younger, 
prescribed more concomitant medications, and with more psychiatric disorders and a 
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prescription history of more opioids in larger amounts; they also use more medical 
services [132]. Studies on genetics may provide better understanding of drug 
addiction. Copy number variations in the human genome may contribute to 
susceptibility or resistance to opioid dependency [133].  
7.3	  Drug	  abuse	  in	  Finland	  
The lifetime prevalence of any illicit drug use among Finns in 2010 was, according 
to population surveys, 17%, and the most common illegal drug was cannabis (Table 
2). Lifetime prevalence of non-medical prescription-drug use in 2010 was 7%, and 
of these drug abusers, 44% had also tried illicit drugs [118]. The prevalence of 
problem users of opioids has been estimated as based on Finnish health care 
registers. This register data come from various hospital discharge registers, the 
national police information system, the register of those caught driving under the 
influence of drugs, and from the national infectious diseases register, hepatitis C 
cases. In 2005, problem opioid users numbered 3,700 to 4,900, or 0.13 to 0.18% of 
the Finnish population [134]. In 2012, problem opioid users numbered 12,700 to 
15,100, rising to 0.38 to 0.45% [135]. Based on these figures, drug abuse in Finland 
has clearly increased.  
Buprenorphine has been the most commonly abused opioid in Finland since the 
first years of the 21st century [136]. Reasons for its abuse include treatment of 
addiction or withdrawal symptoms, as well as recreational use and euphoria seeking. 
Self-treating is common among regular intravenous drug users, of whom 78% 
reported their reason for buprenorphine abuse to be self-treatment; only 10% had a 
recreational purpose [32].  
Polydrug abuse enhances the positive effects of other drugs, such as euphoria 
[137]. Lintonen et al. forecast that by the year 2020, misuse of medicinal drugs and 
synthetic designer drugs, and the growing of cannabis at home will increase 
markedly [138]. Increasing abuse of medicinal drugs will lead to an increasing 
number of drug-related deaths [138]. Population aging will not reduce drug abuse, 
but the Finnish drug-abuser population seems to become older [138]. This 
phenomenon leads to increased need for health care services and OMT, which 
usually is a long-lasting therapy taking years or even the rest of one’s life. 
 
 
Table 2. Lifetime prevalences (%) of illicit drug use among Finns aged 15 to 69 
according to population survey data from Metso et al. [119].  
 
 2002 2006 2010 
Any illegal drug 12 14 17 
Cannabis 12 13 17 
Amphetamine 2 2 2 
Heroin or morphine 1   
Heroin    0 0 
Buprenorphine or other opioidsa  1  
Buprenorphine     1 
Other opioidsa   1 
Sedatives, anxiolytics, analgesics 7 7 6 




Finnish drug users have typically been rather young, but this situation may be 
changing. In 2007, fatal intoxications among drug addicts had the highest frequency 
in the age group 25 to 29 years, but in 2012, in the group 30 to 34 [139]. Typical for 
Finnish drug abusers is mixed use of medicinal opioids, alcohol, and 
benzodiazepines [118,120,121,137,140,141]. Intravenous buprenorphine abuse is 
particularly common among young people [121]. Mixed drug and alcohol 
consumption is responsible for the majority of drug-related deaths in Finland. Piispa 
et al. divided fatal drug use into three groups: compulsive and addictive drug use, 
uncontrolled mixed abuse of various substances, and self-medication of mental and 
physical disorders [140]. Concomitant and risky alcohol- and various-medication 
consumption frequently occur, especially among young people. Mental and somatic 
health problems and various social problems are common among drug abusers and 
in drug-related deaths [118,140].  
When compared to other Nordic countries, Finland’s drug-abuse profile widely 
differs [27,139]. In 2007, the most common cause of death in fatal poisoning in 
Finland was buprenorphine, in Denmark methadone, and in Norway and Sweden 
heroin [27]. In 2012, heroin maintained its position in Norway, but methadone led 
among Swedish opioid poisonings, and buprenorphine and other prescription opioids 
have become more frequent findings in opioid deaths also in Sweden and Norway 
[139].  
7.4	  Other	  prescription	  drugs	  with	  abuse	  potential	  
Opioids with their stronger euphoric effects may serve as the most desired and 
addictive drugs-of-abuse. Apart from benzodiazepines, the Z-drugs (zopiclone, 
zolpidem, zaleplone) and gabapentinoids, many other possible alternatives to 
prescription drug abuse exist. ADHD medications such as methylphenidate [122] are 
amphetamine-like stimulants. High-dose use of the cough syrup dextromethorphan 
may induce dissociative hallucinations or mild euphoric effects [142]. The 
antidepressant bupropion may produce stimulating, amphetamine- or cocaine-like 
effects at high doses [117,143]. Anesthetic ketamine use may lead to out-of-body 
experiences, alteration of one’s sense of time, hallucinations, and dissociative as 
well as sedative effects [144]. With subanesthetic doses, the anesthetic propofol may 
produce euphoria, disinhibition, and sedation [145]. Antipsychotic quetiapine abuse 
may mostly derive from its easy availability for polysubstance-dependent 
individuals [146], although it also has the anxiolytic, calming, and sedative 
properties that drug-abusers seek [147]. A muscle-relaxant, carisoprodol, which 
metabolizes to the anxiolytic meprobamat, has substantial abuse potential, and The 
European Medicines Agency has recommended its being removed from the market 
in Europe [148]. Data on other muscle-relaxant abuse are scarce, but drug abusers 
seem to abuse the muscle-relaxant tizanidine, possibly because of its sedative 
effects. Sedative properties also appear in older-generation antihistamines. 
27 
 
8	  Opioid	  maintenance	  treatment	  
8.1	  	  Need	  for	  treatment	  
According to ICD-10, the diagnostic criteria of opioid dependence include craving 
for opioids, difficulties in controlling opioid use, physiological withdrawal, 
increased tolerance, higher priority assigned to opioids than to other interests, and 
persistent opioid use despite its harmful consequences [149]. Means of treating 
opioid dependence include agonist therapy with buprenorphine or methadone, 
withdrawal therapy with lofexidin, clonidine, or other medications, antagonist 
therapy with naltrexone, and psychosocial therapy [150]. Naltrexone antagonist 
therapy is suitable only for those highly motivated, in order to prevent relapses, 
usually after the acute withdrawal treatment. Psychosocial therapy improves results 
when combined with medications, but is only rarely the choice, due to its immediate 
costs. Treatment for other drug dependencies, such as dependence upon 
hallucinogens, stimulants, cannabis, or amphetamines, involve mainly symptomatic 
treatment. [150] 
OMT has proven efficient in diminishing opioid-related mortality 
[77,84,85,151]. In 2009, the number of patients in OMT in Finland was estimated at 
approximately 1,800 [152]. In November 2011, this number was 2,439 [152]. In 
2012, problem opioid users, including patients in OMT, numbered 12,700 to 15,100 
[135]. Based on these numbers, Ollgren et al. conclude that only 20% of the problem 
opioid users in Finland receive OMT, whereas on a European scale, the estimated 
percentage is over 50% [135,151]. 
8.2	  Treatment	  organization	  
According to the Finnish Act on Welfare for Substance Abusers (41/1986), a 
municipality should organize appropriate treatment for substance abusers [153]. 
OMT is administered according to the Decree of the Ministry of Social Affairs and 
Health on the detoxification and substitution treatment of opioid addicts with certain 
medicinal products (33/2008) [154]. Inclusion criteria for OMT necessarily include 
opioid dependency (according to the ICD-10) and a failed attempt at opioid 
withdrawal treatment [150]. The patient must have a treatment plan with 
medications and know the goal of the treatment, other medicinal and psychosocial 
treatment, rehabilitation, and follow-up of the treatment [150]. A proper therapeutic 
relationship involving doctor and patient is a key factor, but laboratory methods may 
also be applicable in screening and monitoring drug abusers [150]. 
Withdrawal treatment (2% of the OMT patients in 2011) aims to stop all use of 
narcotics, including OMT medications [152]. Rehabilitative substitution treatment 
(73%) aims at rehabilitation and coming off narcotics [152]. Harm-reducing 
substitution treatment (24%) aims at improving the quality of life and reducing drug-
related harm, such as illegal opioid use, injection, infection, and crime [152].  
OMT can be given in specialized addiction treatment units (66% of the Finnish 
patients in 2011), health care centers (21%), specialized health care (11%), or in 
prisons (2%) [152]. OMT medications are delivered from the units daily, but 
patients well committed to the program may receive home medications for 1 to 7 
days at a time, sometimes 15 days. Need for proper control of drug abuse remains, 
because OMT medications also have abuse potential. To prevent intravenous 
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methadone abuse, for example, methadone distributed from the OMT centers is 
diluted with juice. 
Patients have the possibility of receiving their BNX medication at a designated 
pharmacy on the basis of the so-called pharmacy agreement, and in 2011, 7% of the 
patients in rehabilitative substitution treatment received their medications from such 
a designated pharmacy [152]. These patients need regular contact with their 
treatment unit, because they may have relapses in drug abstinence. The first 
experiences of BNX dispensing in designated Finnish pharmacies have been 
considered positive, with only 26% of the pharmacies reported any relevant 
problems [155].	  OMT medications are free for patients attending treatment units, but 
the patients must pay for the medications themselves when received from their 
designated pharmacies.  
8.3	  OMT	  medications	  
The choice between buprenorphine and methadone should be based on individual 
considerations [150]. According to the latest Cochrane review, buprenorphine and 
methadone suppressed opioid use equally, but methadone seemed to be superior to 
buprenorphine in retaining patients in treatment when used with flexible doses 
adjusted to patient need [12]. With fixed medium or high doses, no differences 
between buprenorphine and methadone were detectable [12].  
According to WHO, buprenorphine products should generally be used in weaker 
and methadone in stronger opioid addiction, but those who inject buprenorphine 
should primarily be treated with methadone. Buprenorphine maintenance treatment 
appears to be, however, an effective treatment also for opioid dependents using 
mainly buprenorphine intravenously [156]. Choosing between methadone and 
buprenorphine is not straightforward. On the one hand, if buprenorphine has been 
the main drug causing opioid dependency, one could argue why treat drug addicts 
with that same opioid. On the other hand, giving the stronger full opioid-receptor 
agonist methadone to treat dependency upon a weaker opioid might seem 
controversial. In Finland, opioid dependence has been mainly associated with 
intravenous buprenorphine abuse since the early 2000’s, but use of BNX in OMT is 
high. In 2011, 58% of the patients in OMT received buprenorphine-naloxone, 38% 
methadone, and 4% buprenorphine [152]. 
The European Medicines Agency’s Pharmacovigilance Risk Assessment 
Committee recommended in July 2014 suspension of the commercial oral 
methadone solution available in Finland, Norway, and Sweden, because it contains 
the additive high-molecular-weight povidone [157]. Based on adverse events in 
Norway, this povidone accumulates in cells of vital organs when abused 
intravenously [157]. In Finland, a commercial methadone solution with this type of 
povidone as an additive is currently used in many OMT clinics with special 




9	  Prescription	  drug	  consumption	  and	  abuse	  
Since the beginning of the 21st century, prescription opioid consumption and opioid-
related deaths have increased worldwide [151,158]. More specifically, fatal and non-
fatal heroin poisonings have decreased, while mortality due to prescription opioids 
has increased [159]. Reasons for prescription opioid abuse include safety 
misconceptions, drug purity, easy transportation, and easy availability. More opioid 
prescription and consumption may lead to increasing abuse rates. In the United 
States, urine drug-screening among chronic-pain patients on opioid medications 
revealed that 75% of the patients took their medications contrary to the prescription 
[160].  
Registered prescription opioid sales have increased in Finland in DDD (defined 
daily doses)/1,000 inhabitants/day from 10 in 2000 to 16.5 in 2011 (Table 3). Sales 
of codeine have almost doubled, but sales of tramadol have increased by only less 
than a third. Sales of buprenorphine and methadone for OMT have increased, as 
have the numbers of patients under treatment, but sales of buprenorphine as an 
analgesic have also increased markedly. Although these increases in prescription 
opioid consumption and abuse seem evident, the differing abuser profiles of 
prescription opioids on a national scale have been unclear until the results of Studies 
III and IV. 
The struggle against increasing prescription opioid abuse has inspired 
development of abuse-deterrent formulations to prevent parenteral opioid abuse. 
These include, for example, tablets physically resistant to crushing and dissolving, 
agonist-antagonist combination products, and products incorporated with aversive 
ingredients when administered by the nasal route [165]. Although these abuse-
deterrent formulations reduce the abuse potential of these drugs, they may shift 
opioid consumption further towards other prescription-opioid formulations or even 
towards illegal opioids [166]. After publication of the original articles in this thesis 
study, heroin deaths have, indeed, increased in certain areas. In North Carolina in the 
United States, heroin overdose deaths have increased markedly: in January 2007, for 
each heroin death, 16 prescription opioid deaths occurred, but in December 2013, 
only three [167]. In that state, a transition to heroin had, however, already begun, 
prior to their introduction of tamper-resistant prescription opioids [167]. In Florida 
during 2011-2012, heroin-caused mortality increased, while benzodiazepine- and 
opioid-related deaths decreased, possibly due to a stronger regulation policy for 
prescription medications [168]. 
Real-time electronic prescription databases in some jurisdictions in the United 
States prevent prescription drug abuse [169]. In Finland, as well, electronic 
prescriptions should reduce drug abuse. A patient can, in general, prohibit 
prescription inquiries from doctors other than the one who prescribed the 
medication, but the prescribing doctor is allowed to see all prescription data on 
narcotic medications and medications mainly acting on the CNS [170]. A patient is 
allowed to receive prescriptions on paper upon request until the first of January 
2017, unless the prescription is for mainly CNS-acting or narcotic medications. All 
prescriptions for the latter should be electronic from the beginning of 2015. Only 
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small private practices handling fewer than 5,000 prescriptions per year may still use 
prescriptions on paper until the first of January 2017. [170] 
Customs play a significant role in preventing illegal importation of addictive 
drugs. If such drugs pass Customs, the police attempt to stop their distribution. In 
Sweden, only 20% of those who died of buprenorphine or methadone poisoning had 
a filled prescription for these drugs, suggesting that the majority of abusers 
purchased their drugs from illegal sources [171]. Today’s societies are confronting a 
struggle between a need to diminish illegal use and to support patients needing 
efficient pain- and OMT medication. 
 
 
Table 3. Opioid and gabapentinoid sales in Finland, data from Finnish Statistics on 
Medicines 2000-2012 [161-164].  
  DDD/1,000 inhabitants/day  
 DDD 
(mg) 
2000 2004 2008 2011 Products 
Buprenorphine, 
analgesic 












 5.22 8.50 9.86 10.11 Tablet (with paracetamol 
or ibuprofen), oral solution 
(cough syrup) 
Fentanyl 1.2/0.6 a - 0.92 1.47 1.19 Soluble tablet, injection, 
soluble film, transdermal 
patch, nasal spray 
Methadone, OMT 25 0.02 0.05 0.06 0.14 Oral solution 
 
Morphine 100/30 b 0.29 0.23 0.23 0.27 Prolonged-release tablet, 
oral solution, injection 





75 - - - 0.08 Prolonged-release tablet 
(with naloxone) 
Tramadol 300 2.22 2.77 2.96 2.99 Injection, prolonged-
release tablet, capsule, 
suppository 
Pregabalin 300 - - 3.39 4.74 Capsule 
 
Gabapentin 1800 0.31 1.14 0.96 1.04 Capsule, tablet 
 
a 1.2 mg in transdermal patches, 0.6 mg in soluble tablet  
b 100 mg in prolonged-release tablets, 30 mg for injection 




AIMS	  OF	  THE	  STUDY	  
The objectives of this thesis were to determine 
 
• the typical features and laboratory findings characterizing fatal opioid and 
gabapentinoid poisonings and other opioid- and gabapentinoid-related deaths 
(I─IV) 
• means of interpreting postmortem opioid and gabapentinoid concentrations in 
suspected fatal drug poisonings and means to to utilize this drug concentration 
data in cause-of-death investigation (I─IV) 
• abuser profiles of prescription opioids (I─III) and gabapentinoids (IV) 
• the urinary naloxone concentration able to differentiate parenteral 
buprenorphine-naloxone (BNX) abuse from other buprenorphine use (V), and, 
based on this, the proportion of parenteral BNX abuse-associated deaths among 
all buprenorphine-related deaths (VI) 
• means to utilize postmortem data and toxicological laboratory analyses in public 




MATERIALS	  AND	  METHODS	  
1	  Postmortem	  cases	  
1.1	  Medico-­legal	  autopsy	  data	  
An unexpected death in Finland leads to a medico-legal cause-of-death 
investigation. Such cases that are known or are suspected to be attributable to 
accident, crime, suicide, poisoning, occupational disease, medical procedure, or war 
should always undergo medico-legal examination. The police determine the need for 
medico-legal death investigation; no permission is required from the bereaved. Of 
the approximately 50,000 deaths in Finland annually, a medico-legal investigation 
occurs in about one-fifth. This investigation includes autopsy with additional 
investigations, often including toxicological analysis, which should always be 
performed in suspected poisonings, suicides, traffic accidents, and in cases with no 
specific cause of death. Samples from over 6,000 of those deceased annually 
undergo toxicological analysis. The Toxicology Laboratory of the Department of 
Forensic Medicine, University of Helsinki, performs all forensic toxicology in 
Finland. This laboratory has been since 1997 an accredited laboratory by the Finnish 
Centre for Metrology and Accreditation (FINAS).  
Toxicological samples were taken during the autopsy. The blood and urine 
samples for quantitative analyses contained 1% sodium fluoride to prevent microbial 
alteration, and the blood samples came from femoral venous blood. When 
toxicological samples arrived at the laboratory, they remained stored at +4	  oC until 
analysis was completed, after which they were stored at -20 oC.  
The postmortem toxicology database included a forensic pathologist’s referral, 
laboratory analysis results, and information extracted from the final death certificate. 
The referral included a brief description of the circumstances of death, preliminary 
laboratory analysis requests, macroscopic autopsy findings, information on the drugs 
the deceased probably had used, and age and gender. Laboratory data included the 
drug-analysis results and analysis of other substances found in the specimens. The 
final death certificate included the cause of death according to ICD-10, and the 
manner of death according to WHO. A forensic pathologist determines the manner 
of death according to all autopsy and toxicological data, and background 
information. Accident as the manner of death may contribute to both unintentional 
drug overdose or trauma. 
According to Finnish legislation, medical record use without personal identifiers 
is allowed for medical and health research with permission from the institute, 
without special ethics-committee approval. 
1.2 Postmortem	  studies	  
The primary postmortem data covered all forensic toxicology cases registered in 
Finland during 2000 to 2008 and 2010 to 2011 (Figure 2). Studies I and II included 
1,363 opioid-positive cases of those deceased aged 14 to 44. The age limit was set in 
order to exclude all those other than abusers.  Drug abuse among Finnish drug 
abusers during 1997 and 2008 was concentrated in the age group 15 to 44, with drug 
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abusers above 45 representing only 2% of all drug abusers [141]. In other studies 
(III-IV,VI), all cases underwent thorough individual examination to classify the 
abuse- and other-use cases. The case numbers of Studies III, IV, and VI were, 
respectively, 2,088, 359, and 225. Criteria to define abuser cases were one or several 
findings among the following: known history of drug abuse or addiction, known 
recent parenteral drug self-administration or signs of it, such as new injection marks 
or injection equipment located near the deceased, and laboratory analysis results of 
illicit substances such as amphetamine, cannabis, or designer drugs. The other-use 
cases refer both to medical use and non-medical misuse, such as drug-induced 









2	  Urine	  samples	  from	  living	  patients	  
Study V utilized 40 consecutively collected urine samples from 32 living opioid-
dependent patients at three different phases of the OMT in the Department of 
Psychiatry, Helsinki University Central Hospital. The urine samples were collected 
under supervision. The Toxicology Laboratory of the Department of Forensic 
Medicine performed the opioid analysis similarly to its analyses of postmortem 
samples. The Institutional Review Board of the Department of Psychiatry, Helsinki 
University Central Hospital, approved the protocol of Study V.  
3	  Laboratory	  methods	  
Toxicological analysis followed a comprehensive multi-technique approach. Urine 
drug-screening was by a liquid chromatography time-of-flight mass spectrometry 
(LC-TOFMS) method for approximately 700 drugs [172,173]. Quantitative blood-
sample screening for 200 drugs comprised gas chromatography with nitrogen 
phosphorus detection (GC-NPD) for acidic or neutral drugs [174], GC with electron 
capture detection (GC-ECD) for benzodiazepines [175], and GC-NPD for basic 
drugs [176]. Opioid analysis consisted of liquid-chromatography-tandem mass 
spectrometry (LC-MS/MS) [177]. Quantitative confirmation analyses for both urine 
and blood were carried out by GC-MS and LC-MS/MS. Ethanol analysis in blood 
samples was based on headspace GC analysis.  An alcohol concentration over 0.5‰ 
determined a positive alcohol record in Studies I to IV and VI. 
New LC-MS/MS laboratory methods were developed and validated for 
measuring cocentrations of pregabalin and gabapentin (IV), and naloxone (V).  
4	  Drug	  concentration	  data	  
The Laboratory of Toxicology provides for all toxicology certificates the whole 
blood drug concentrations measured, as well as forensic reference concentrations in 
plasma, on which forensic pathologists base their conclusions as to postmortem 
whole blood concentrations and these drugs’ contribution to death. The forensic 
plasma reference concentrations (Table 4) are based on published compilations and 





Table 4. Reference concentrations in plasma available to forensic pathologists, 
along with laboratory results, for interpretation of postmortem whole blood 
concentrations. 
 






Tramadol ad 0.6 
Pregabalin 2.8-8.3 
Gabapentin 2-6 





To calculate the frequency of different benzodiazepine findings in Studies I and 
II, a concentration limit was set to distinguish benzodiazepines from their 
metabolites. If the concentration of a possible metabolite was less than 10% of the 
parent-drug concentration, the compound was regarded as a metabolite, and 
concentrations over 10% implied the parent drug, unless the referral provided more 
accurate information. This allowed calculation in each case of the number of actual 
benzodiazepine findings, excluding metabolites. 
5	  Statistical	  methods	  
Drug concentration data were skewed: the concentrations were mainly low, within 
the therapeutic range, but also some very high concentrations occurred. Due to the 
skewed data, the medians represented statistics for the concentration data. 
Difference between groups, such as between abuse and other use, was tested by 
Kruskall-Wallis and Mann-Whitney tests for independent samples. The statistical 
analyses tool in Studies I, II, V and VI was SPSS 15.0 (SPSS Inc, Chicago, IL, 





RESULTS	  AND	  DISCUSSION	  
1	  Fatal	  poisonings	  
1.1 Opioid	  poisonings	  
Since the year 2000, the total number of fatal prescription opioid poisonings in 
Finland has notably increased (Figure 3). During recent years, opioid poisonings 
have numbered almost 200 (Figure 3). A case was classified as opioid poisoning if 
an opioid emerged in laboratory data, and a forensic pathologist had determined the 
cause of death as poisoning by that opioid. Other opioid-related cases included 
opioid findings, but the cause of death was other than poisoning. Accidental opioid 
poisonings usually involve drug abuse, but some poisonings are intentional suicides. 
The profile of opioid findings has changed during the last decade. Buprenorphine 
has replaced heroin, and dextropropoxyphene no longer is available in the 





Figure 3. Number of fatal opioid poisonings in Finland 2000-2012, data from the 
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The steep rise in opioid-related deaths among Finns aged 14 to 44 during 2007-
2008 seems to have abated during 2010-2011 (Figure 4). Most opioid poisonings 
proved to be polysubstance poisonings (I, II, Figure 4). During 2000-2008, 
concomitant opioids were most common in methadone poisonings (27%), followed 
by tramadol (19%), codeine (15%), and buprenorphine (8%). In codeine and 
buprenorphine poisonings, concomitant opioids were, however, less frequent than in 
other codeine and buprenorphine deaths. In 2007-2008, concomitant opioid findings 
increased markedly (Figure 4).   
Findings of benzodiazepines or alcohol >0.5‰ or of both were connected with 
90% or more of the opioid poisonings, and benzodiazepines with 82% (I). 
Benzodiazepine findings and findings of more than two benzodiazepines were 
significantly more common in fatal poisonings than in other deaths in codeine, 
fentanyl, and buprenorphine cases (I), but no statistical difference appeared for 
methadone (I) nor oxycodone (unpublished data from I). In Sweden during 2005-
2010, concomitant benzodiazepines were involved in only 30% of fatal 
buprenorphine and methadone poisonings [171], markedly less than in this thesis 
study. Compared to deaths other than poisonings, alcohol findings in tramadol 
poisonings were less frequent (15%) (I). Alcohol findings were more frequent in 
buprenorphine (58%) (I) and oxycodone (48%) poisonings than they were in other 
deaths (unpublished results from I). 
In fatal poisonings, median blood concentrations of codeine, tramadol, fentanyl, 
and oxycodone were over their respective therapeutic upper limits (Tables 4, 5). 
Buprenorphine and methadone concentrations in fatal poisonings were low, with no 
clinical difference detectable between poisonings and other cases (I, II, Table 5). 
Other studies have confirmed these results. In methadone-related deaths in Norway, 
median methadone concentrations were within therapeutic range, with no significant 
concentration differences between methadone poisonings and other methadone 
deaths [91]. A Swedish study confirmed the same findings regarding buprenorphine 
[178]. 
To distinguish codeine and tramadol poisonings from deaths other than 
poisonings, the concentrations of their active metabolites, morphine and O-
desmethyltramadol, were analyzed. Concentrations of morphine were rather similar 
both in poisonings and in other cases, but the median codeine/morphine 
concentration ratio was significantly higher in fatal poisonings (22.5) than in other 
deaths (5.9) (I). The median concentration of O-desmethyltramadol was 
significantly higher in poisonings (0.8 mg/l) than in other cases (0.2 mg/l), but the 
concentration ratio tramadol/O-desmethyltramadol did not differ significantly 
between poisonings and other deaths (I). 
Accidental overdose was a very typical manner of death in buprenorphine (94%), 
methadone (94%), and fentanyl (90%) poisonings (I, II, and unpublished data from 
I). Among oxycodone poisonings, accidental deaths were also common (65%), and 
in quite a few cases, the manner of death remained unclear (22%) (unpublished 
results from I). Accidental codeine (43%) and tramadol (55%) poisoning rates were 
followed by those for suicides (40% of codeine and 31% of tramadol poisonings) 
(I).  
Median age at poisoning was for buprenorphine 27, for oxycodone 28, for 
tramadol 29, for methadone 30, for fentanyl 31, and for codeine 32, these differences 
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being statistically nonsignificant (I, in part unpublished). In Sweden in 2005-2010, 
in contrast, those who died of buprenorphine poisoning were significantly younger 





Figure 4. Opioid deaths in age group 14 to 44 during 2000-2011 (data from I, II, 
III, and unpublished data). 
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1.2	  Buprenorphine	  poisonings	  
Of all the 391 buprenorphine cases in 2000-2008, fatal poisonings constituted 47% 
(II). Buprenorphine deaths were usually delayed and occurred during sleep (II). 
Death was immediate in 10% of the buprenorphine poisonings, occurring within half 
an hour of buprenorphine self-administration, whereas death was delayed in 52%, 
and the course of events remained unknown in 38% (II). Median buprenorphine 
concentrations in immediate buprenorphine poisonings (3 µg/l) and delayed 
buprenorphine poisonings (1.2 µg/l) were both situated within the lower half of the 
therapeutic range, although they differed from each other statistically (II). The 
blood/plasma ratio for buprenorphine is close to unity [9], implying that 
buprenorphine plasma and whole blood concentrations are rather similar.  
The norbuprenorphine/buprenorphine (NOR/BPN) ratio was lower in the 
buprenorphine poisonings than other cases, indicating that in such poisonings, death 
had occurred soon after dosing (II, III). The half-life of NOR is longer than that of 
BPN (Table 1), which leads to higher NOR concentrations when more time has 
passed after drug administration. In fatal buprenorphine poisonings, the NOR/BPN 
ratio was generally <1, and in other causes of death, close to 1 or >1 (II, III). The 
difference was even more evident when measuring this NOR/BPN ratio in urine 
(Table 5).  
In fatal poisonings, the administration route was mostly parenteral, but in other 
buprenorphine-related deaths, sublingual. In intravenous buprenorphine 
administration, no first-pass metabolism occurs, which leads to a lower NOR/BPN 
ratio than in buccal or sublingual administration. 
All but one buprenorphine poisoning included concomitant drugs or alcohol (I, 
II, III). Buprenorphine poisonings are usually polydrug poisonings. In Sweden, 
mono-intoxications among the 41 fatal buprenorphine poisonings numbered 4 [178]. 
Benzodiazepines were involved in 82% of the fatal buprenorphine poisonings 
(II). One benzodiazepine appeared in 31% of the buprenorphine poisonings, two in 
36%, and three or four in 15%. The most frequent benzodiazepines were alprazolam, 
diazepam, temazepam, and oxazepam (II). In Sweden, 75% of buprenorphine 
poisonings included hypnotics or sedatives, most frequently alprazolam (in 41% of 
the buprenorphine poisonings) [178]. The median concentration of alprazolam in 
Study II (0.06 mg/l) was slightly higher than its upper therapeutic limit of 0.05 mg/l 
[179], but the other median benzodiazepine concentrations remained within their 
therapeutic ranges (II). These results are in concordance with the Swedish study 
reporting that alprazolam concentrations were in the upper half or above the 
therapeutic range, whereas diazepam and other benzodiazepine concentrations were 
lower [178]. 
Although benzodiazepines and alcohol in buprenorphine poisoning, compared to 
their occurrence in other deaths, were more common, concomitant opioids were 
rather rare: during 2000-2008, 92% of the buprenorphine poisonings included no 
concomitant opioids, and only one additional opioid was present in the remaining 
8% (II). This was significantly lower than the figure of 21% of concomitant opioids 
in other buprenorphine deaths (II). When other opioids were present, their 
concentrations were lower in buprenorphine poisonings than in other cases (II).  
During 2010-2011, concomitant opioids in buprenorphine poisonings of those 
deceased aged 14 to 44 (23%) were less common than in other buprenorphine-
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related deaths (36%) (unpublished results from III), although the percentage of 
concomitant opioids had almost tripled since 2000-2008.  
 
1.3	  Benzodiazepine	  poisonings	  
In Studies I and II, of the 1,363 opioid-positive cases, 1,022 included 
benzodiazepines, and only 34 cases were classified as benzodiazepine poisonings, 
leading to a benzodiazepine poisoning proportion of 3.3%. Alprazolam poisonings 
were mostly accidents (14/20), and zopiclone and zolpidem poisonings, suicides 
(8/14). Alprazolam poisonings were connected with buprenorphine, amphetamine, 
and cannabis use, whereas zopiclone and zolpidem poisonings mainly included the 
weak prescription opioids codeine, tramadol, and dextropropoxyphene, as well as 




Table 5. Comparison of findings and opioid concentrations (C) in fatal poisonings 
among those deceased aged from 14 to 44 years among Studies I, II, III, and VI.  








2000-2008  Buprenorphine 391 182 (46.5) 1.4* 1.2* 
(I, II) NOR/BPN ratio 291 182 (-) 0.56* 1.16* 
 Methadone 102 48 (47.1) 0.35 0.30 
 Codeine 360 146 (40.6) 1.4* 0.09* 
 Tramadol 348 117 (33.6) 5.3* 0.6* 
 Fentanylb 43 20 (46.5) 15* 4.6* 
 Oxycodoneb 98 21 (21.4) 0.28* 0.08* 
 Benzodiazepinesb 1,022 34 (3.3) - - 
      
2010-2011  Buprenorphine, bloodb 251 107 (42.6) 1.3 0.97 
(III) Buprenorphine, urineb 245 81 (33.1) 51* 21* 
 Methadoneb 54 29 (53.7) 0.50 0.40 
 Codeineb 92 33 (35.9) 1.4* 0.14* 
 Tramadolb 108 55 (50.9) 5.6* 0.8* 
 Fentanylb 28 24 (85.7) 8.1* 3.4* 
 Oxycodoneb 29 14 (48.3) 0.38* 0.12* 
      
1/1/2010-  Buprenorphine, bloodb 213 66 (31.0) 1.2* 0.66* 
30/6/2011 Buprenorphine, urineb 211 67 (31.8) 83* 25* 
(VI) NOR/BPN, bloodb 193 60 (31.1) 0.65 0.85 
 NOR/BPN, urineb 214 65 (30.4) 0.20* 1.23* 
a postmortem blood concentrations unless stated otherwise; in mg/l, except in µg/l 
for buprenorphine and fentanyl 
b  unpublished concentration data  
* denotes a statistically significant difference in concentration medians between 




1.4	  Gabapentinoid	  poisonings	  
During 2010-2011, pregabalin findings numbered 316 and gabapentin 43 (IV). Fatal 
poisonings were somewhat rare: poisonings comprised 10% of all the pregabalin- 
and 5% of the gabapentin-related deaths (IV). Of the drug-abuser cases, pregabalin 
poisonings involved 19% and gabapentin poisonings 13% (IV). Concentrations in 
gabapentinoid poisonings were high. Forensic pathologists may have considered 
pregabalin and gabapentin safe substances somewhat similar to benzodiazepines, 
possibly partly because individuals have survived very high gabapentinoid 
concentrations. If an opioid was found, which was the case in about 90% of the 
gabapentinoid poisonings (IV), the opioid had usually been considered the main 
cause of death and gabapentinoid a contributory factor, unless its concentration was 
very high. This is in concordance with another postmortem study of pregabalin cases 
in which, of 15 pregabalin-related deaths with reported peripheral blood 
concentrations, 2 were polydrug poisonings with pregabalin as the main toxin [180]. 
In these pregabalin poisonings, its concentrations in peripheral blood were high: 
206.7 and 45.3 mg/l, whereas the median pregabalin concentration in all cases was 
6.4 mg/l [180]. 
Pregabalin was present in a quarter of fatal opioid poisonings (Table 6). It was a 
common finding in codeine- and tramadol-abuser cases, which may be connected to 
the fact that all the three of these are easily prescribed with normal prescription 
practices.  
In the abuser cases in fatal pregabalin poisonings, pregabalin median 
concentration, 29.5 mg/l, was higher than the median 15 mg/l for abuser cases 
overall, and, compared to its therapeutic range, clearly above it (Table 4). Only one 
case of gabapentin poisoning was attributed to drug abuse, and the gabapentin 
concentration in that case, 45 mg/l, was markedly higher than the median 




Table 6. Pregabalin (PRG) findings in fatal opioid poisonings (unpublished data 
from III, IV). 










Buprenorphine 117 29 (24.8) 114 27 (23.7) 
Codeine 87 16 (18.4) 33 11 (33.3) 
Fentanyl 28 3 (10.7) 25 3 (12.0) 
Methadone 34 11 (32.4) 34 11 (32.4) 
Oxycodone 33 6 (18.2) 16 2 (12.5) 
Tramadol 86 30 (34.9) 56 25 (44.6) 






2	  Prescription	  opioid	  and	  gabapentinoid	  abuse	  	  
2.1	  Abuser	  profiles	  
The proportions of drug-abuser cases among all cases related to each drug were for 
buprenorphine 86%, for methadone 82%, for tramadol 29%, for codeine 16%, for 
fentanyl 15%, for oxycodone 7%, for pregabalin 48%, and for gabapentin 19% 
(Figure 5).  
Abusers were aged 18 to 74 years. The median age in the abuser group ranged 
from 30 to 35, and among users who were not abusers, from 47 to 75 (III, IV). 
Buprenorphine-, fentanyl-, pregabalin- and gabapentin abusers were the youngest, 
median age 30, whereas the median age of tramadol abusers was 32, and codeine-, 
methadone-, and oxycodone users were the oldest, median 35. Men dominated both 
the abuser- and other-user statistics (76% of codeine and 75% of gabapentin abusers, 
and of other abusers of opioids and pregabalin, 84-87%). Drug abusers were, then, 
mainly young men. (III, IV) 
Fatal poisonings were more common in opioid-abuser deaths than in other 
deaths, the proportions of fatal poisonings ranging from codeine-abusers’ 27% to the 
fentanyl-abusers’ 78%. Poisonings caused by abuse of pregabalin (19%) or 
gabapentin (13%) were less frequent. The proportion of accidental deaths of abusers 




Figure 5. Proportion of  abuse findings among all findings for opioids and 
gabapentinoids in medico-legal cause-of-death investigations in Finland during 


























Buprenorphine and methadone concentrations in abuser deaths were low, only 
1.2 µg/l for buprenorphine and 0.40 mg/l for methadone (III). Buprenorphine and 
methadone findings concentrated in younger age groups, and these two drugs were 
mostly abused (Figure 6). Fentanyl abuser deaths proved to be mainly related to 
accidental poisonings, and the median abuse concentration, 8.2 µg/l, fell within the 
reference plasma concentration range, although near the upper limit (Table 4). 
Unlike other strong opioids, the median concentration of oxycodone in abuser cases, 
0.24 mg/l, was 2.4 times as high as its therapeutic limit (III). Oxycodone abuse was 
rare, but when abused, it was attributed to polyopioid abuse, including concomitant 
opioids in 56% of the abuse cases (III). Consistent with these findings, oxycodone 
abuse has been suspected to involve rather disadvantaged polydrug abusers using 
whatever drugs they could get their hands on [181]. Pregabalin and tramadol showed 
considerable abuse among the youngest age groups (Figure 6). 
Approximately 90% of the pregabalin- and gabapentin-abuser cases included 
opioids (IV), and among opioid-related deaths, 26% of the opioid-abuser cases 
involved gabapentinoids (unpublished data from III, IV). This proportion is of the 
same magnitude as in a recent report on methadone maintenance treatment showing 
gabapentinoid abuse to be present among 22% of the patients [57]. Cases of driving 
under the influence of drugs in Finland have also revealed recreational pregabalin 
use concomitantly with that of other psychoactive drugs [125]. 
The median abuse concentrations for weaker drugs were higher, above their 
therapeutic ranges (Table 4): for tramadol 3.1 mg/l, for pregabalin 15 mg/l, for 
codeine 0.27 mg/l, and for gabapentin 8.3 mg/l (III, IV).  Consistently, 
gabapentinoid abusers have been shown to take these drugs at doses clearly 













Figure 6. Comparison between abuse versus other use of opioids and 
gabapentinoids (III, IV). 
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2.2	  Concomitant	  alcohol	  and	  opioid	  findings	  
All abuser cases included drugs acting on the CNS other than opioids or 
gabapentinoids. Among the abuser cases, proportions of concomitant opioid findings 
were for buprenorphine 32%, for methadone 49%, for tramadol 50%, for codeine 
53%, for fentanyl 56%, for oxycodone 56%, for pregabalin 91%, and for gabapentin 
88% (III, IV). Codeine-, oxycodone-, and tramadol-abuser cases involved 
concomitant opioids significantly more often than did other than abuser cases.   
Alcohol abuse is in Finland more common than in many other countries [27], a 
fact paralleled by Finland’s opioid-abuser deaths. Among opioid abusers, alcohol 
was involved in 31% of the deaths, whereas in the United States in 2010, alcohol 
was involved in 22% of deaths related to opioid pain-reliever abuse [183]. Among 
the abuse cases in this thesis study, proportions of positive alcohol findings were for 
buprenorphine 35%, for codeine 33%, for fentanyl 28%, for tramadol 25%, for 
methadone 17%, for oxycodone 12%, for pregabalin 16%, and for gabapentin 22% 
(III, IV). Alcohol findings among abusers compared to other users were more 
frequent among buprenorphine, codeine, and fentanyl cases. Abuser profiles 
between Finland and the United States differed also here: among the opioids studied 
in this thesis, in the United States oxycodone involved alcohol the most (23%) [183], 
but in the Finnish data, oxycodone deaths included the fewest concomitant alcohol 
findings (III). 
3	  Buprenorphine-­naloxone	  abuse	  
3.1	  Naloxone	  concentrations	  in	  OMT	  patients	  
Before their entering OMT, all the patients’ urine samples tested positive for 
buprenorphine at a median of 90 µg/l. The urine naloxone concentration ranged 
from 0 to 300 µg/l, six of them being 0 µg/l. During OMT with BNX, all samples of 
the 32 OMT patients were positive for naloxone. In the stable phase of OMT, the 
naloxone median was 60 µg/l and its range, 5 to 200 µg/l. In the unstable phase, the 
naloxone median was 70 µg/l and range 10 to 1700 µg/l. Median urine naloxone 
concentrations differed statistically significantly between patients before and during 
OMT, but not between the stable and unstable phase in the treatment. (V) 
In the “high naloxone group”, where naloxone (NX) was above 200 µg/l, the 
median NX/BPN ratio was 0.9 and NOR/BPN ratio 1.8, and in the “low naloxone” 
group, with NX≤200 µg/l, the median NX/BPN ratio was 0.3 and NOR/BPN 4.5 
(V). NX has considerable first-pass metabolism and very low oral and sublingual 
bioavailability, which leads to low NX concentrations in sublingual administration. 
Moreover, timing of the urine sample collection influences these ratios and their 
interpretation. A high NX/BPN ratio may imply recent BNX intake because the half-
life of NX is shorter than that of BPN. Concentrations of NX and BPN become 
lower when time has passed after drug administration, with NOR concentration 
remaining high longer. In Study V, no information was available as to drug-
administration time compared to sampling time. Patients in the stable phase of OMT 
should have taken their medications once a day, but the suspected BNX abusers may 
also have taken extra doses.  
In the stable phase, 85% of the urine naloxone concentrations were below 100 
µg/l (5 to 90 µg/l), whereas in the unstable phase, 33% contained naloxone over 100 
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µg/l (V). Hull et al. studied 216 urine samples from 70 patients receiving 8 to 24 mg 
BNX a day and found that in unadulterated samples, urine naloxone concenteration 
was undetectable, with the cut-off 100 µg/l [184]. Based on this and the findings in 
Study V, a threshold of urine naloxone higher than 100 µg/l is suggested to indicate 
parenteral BNX use (VI). An NX/BPN concentration ratio close to or >1, and NX 
concentration above 100 to 200 µg/l, may differentiate parenteral BNX use from 
sublingual use, in which NX/BPN ratio and NX concentration are low. 
3.2	  Buprenorphine-­naloxone	  poisonings	  
Based on laboratory findings from OMT patients, the 225 buprenorphine-related 
deaths were classified into three groups: parenteral BNX (urine NX>100 µg/l), 
parenteral buprenorphine (BPN>50 µg/l and NX 0 µg/l), and other BNX or BPN 
(NX≤100 µg/l, or BPN≤50 µg/l and NX 0). The contribution by parenteral BNX 
abuse was 12% of all the buprenorphine-related deaths (VI). Intravenous BNX has 
been successful in reversing acute opioid overdose [185], but Study VI showed that 
intravenous abuse of BNX may be fatal.  Buprenorphine poisonings were 
proportionally even more common in the parenteral BNX group (68% of parenteral 
BNX cases) than in the parenteral BPN group (31%) (VI). In fatal buprenorphine 
poisonings, the proportion of parenteral BNX abuse was 28% (VI). The median 
NOR/BPN ratio was significantly higher among “Other BNX or BPN” (1.26) than in 
“Parenteral BNX” (0.22) or “Parenteral BPN” (0.26), suggesting that the death had 
occurred more rapidly after drug administration in the parenteral groups, and in the 
other-use group, death was delayed (VI).  
French researchers have concluded that in rats, intravenous BNX use may 
improve buprenorphine safety because naloxone prevents the dose-dependent 
respiratory depression toxicity of norbuprenorphine [114]. The differences in 
respiratory effects between BNX and BPN were, however, significant only in 
combination with diazepam; in that case, respiratory depression rose in opioid-naïve 
rats, but fell in buprenorphine-tolerant rats [115]. This means that BNX may 
contribute less to respiratory depression in a tolerant BNX user who also takes 
benzodiazepines, which, according to Study II, is a highly common practice. The 
impact of naloxone in reducing respiratory depression may, however, not be 
clinically high enough, since fatal buprenorphine poisonings were proportionally 





Traditionally, opioid poisonings are seen as overdose deaths resulting from a too-
large dose of the drug. Because prescription opioids are manufactured by 
pharmaceutical companies with the drug content printed on the package, they are in 
this sense better defined than, for example, illicit heroin. Prescription opioids are, 
however, never a safe alternative in drug abuse. Their abuse may be fatal, even at 
concentrations within their therapeutic ranges. Factors related to opioid deaths 
include polydrug use involving other CNS-depressant drugs or alcohol (I, II), and 
low physical activity: opioid poisonings often are delayed, occurring during sleep 
(II). In unintentional fatal drug poisonings, prescription opioids are the most 
important group of medicines found, often involving drug abuse. Knowing the 
characteristics of drug abuse is vital in preventing its undesirable consequences. 
Unlike with many other drugs, the correlation between opioid blood 
concentration and fatal outcome is low. Opioid concentrations themselves are, 
therefore, insufficient in determining opioid poisonings. Concentrations in both 
buprenorphine poisonings and other abuser cases were low and did not differ much 
between poisonings and other opioid-related deaths (II). Swedish researchers also 
showed that no lethal buprenorphine blood concentration can be defined [178]. 
Buprenorphine poisonings undoubtedly occur, although no rigid fatal-concentration 
limits exist. In distinguishing poisonings from other deaths, tools worth 
consideration include metabolite concentrations and parent/metabolite concentration 
ratios (I). Urine NOR/BPN concentration ratios provided the most evident difference 
between poisonings and other buprenorphine deaths (I, VI). The main factors 
influencing such concentration ratios are administration route, genetic 
polymorphisms, and time of death and of sampling. In oral administration, first-pass 
metabolism may produce more metabolic products than in parenteral administration. 
Information on CYP2D6 genotype would improve interpretation of the 
parent/metabolite ratios of codeine and tramadol, because slow CYP2D6-
metabolizers produce fewer metabolic products of codeine and tramadol. In some 
drug intoxications, in addition, high drug doses may produce autoinhibition, leading 
to a lower ratio of metabolic products, although this has not been detectable among 
opioids. 
Because urine samples undergo routine toxicological screening and 
quantification of drugs of abuse, knowing the urine NOR/BPN concentration could 
help forensic pathologists to determine whether a death was poisoning, despite the 
low buprenorphine concentration. Low postmortem buprenorphine and methadone 
concentrations characterized both abuse cases and other cases (I, II, III). Forensic 
pathologists determine the cause of death not only according to drug concentrations, 
but according to all available documents and autopsy data, including background 
information. In contrast to stronger opioids, concentrations of codeine and tramadol 
among both abusers and other users were above their therapeutic ranges (I, III). 
High drug concentrations may suggest an oral administration route, and low 
concentrations may suggest intravenous administration, because the rapid increase in 
systemic concentrations of opioids with intravenous dosing can be more toxic than 
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their more gradual increase after oral dosing. Iwersen-Bergmann et al. showed that 
among methadone-related deaths, mean methadone concentrations were one-third 
lower in the injecting group [186]. In another study, plasma concentrations of 
tramadol after intravenous administration were higher than after oral administration, 
but after intravenous administration, substantially less increase occurred in the 
concentrations of tramadol’s active metabolite O-desmethyltramadol; the reason is 
that after intravenous administration, no first-pass metabolism occurs [187]. This 
suggests that after intravenous intake, the tramadol/O-desmethyltratmadol ratio 
would be high. In rats, blood tramadol/O-desmethyltramadol ratios in an oral 
administration group and in an intravenous group were, respectively, 2 and 20 [188]. 
In Study I, median tramadol/O-desmethyltramadol ratios in fatal poisonings and 
other-than-fatal poisonings were 7.7 and 6.4, suggesting that tramadol 
administration was mostly oral. 
Postmortem fentanyl concentrations seem somewhat lower after intravenous than 
after transdermal or transmucosal administration. Postmortem fentanyl concentration 
has been lower when it was administered intravenously (mean 8 µg/l, range 5-10 
µg/l, n=3) than transdermally (mean 21 µg/l, range 10-38, n=6) [83]. Postmortem 
femoral blood concentrations after intravenous administration have been in other 
studies 2.7 µg/l and 13.8 µg/l [189], and 13 µg/l [190]. In transdermal 
administration, case reports have revealed a postmortem femoral blood 
concentration of 17.2 µg/l [191], and in transmucosal cases, of 13, 19, 28, and 97 
µg/l [192]. Martin et al. found, in contrast, that postmortem fentanyl concentrations 
were higher following intravenous (mean 53 µg/l, range 3-383 µg/l, n=12) than 
transdermal (mean 15 µg/l, range 3-71 µg/l, n=62) administration [193]. In their 
material, however, of 12 intravenous administration cases, 10 were fentanyl 
poisonings, compared to only 27 of the 64 transdermal cases [193], and in fatal 
poisonings, drug concentrations usually are higher than in other drug-related deaths. 
In addition, the concentration range in intravenous cases was wide, causing a bias in 
the mean; the median in the intravenous cases was 20 µg/l and in the transdermal 
cases 12 µg/l [193]. Clinical concentrations following intravenous fentanyl 
administration are high, but they decline within 1 or 2 hours, whereas 
transmucosally or transdermally administered fentanyl reaches its peak 
concentration more slowly and steadily [96]. Opioid poisonings are usually delayed, 
so intravenously administered opioid concentrations are not peak concentrations but 
may have decreased substantially, even in fatal opioid poisonings. Postmortem 
concentrations may help in differentiating routes of administration, although 
concentration data are insufficient without more background information, because 
low concentrations may also result from inadequate or no tolerance, or from delayed 
death. 
This study revealed that at least 0.5% of all the deceased in Finland during 2010-
2011 had abused opioids as narcotics (III). The figure is close to the estimate of 0.38 
to 0.45% from 2012 based on data collected from various health care registers [135]. 
These rather similar results suggest that comprehensive postmortem database studies 
can also serve in the process of estimating abuse among the living. Surveys based on 
questionnaires provide information on the prevalence of drug abuse, but they suffer 
from low reliability of answers and poor response rates.  Ethnographic studies 
provide information on characteristics of drug abuse, but they are time-consuming 
and lack prevalence information. Studies from adverse databases suffer from 
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underreporting. Prescription database studies exclude over-the-counter products, 
illegal drugs, and medications purchased from treatment units as is most 
buprenorphine and methadone consumed in OMT. Various registers from health 
care in Finland are available, but collecting and unifying data from these registers is 
highly time-consuming, difficult, and requires several ethics-committee approvals. 
By contrast, postmortem toxicology information in Finland comes from one 
comprehensive database. With properly designed study protocols, postmortem 
database studies could be produced even annually with considerably less work than 
needed for register studies or surveys. 
Regularly published lists of postmortem drug findings provide information on 
fatal drug poisonings and drug findings in general. These data reveal trends in drug 
use both in fatal poisonings and in drug occurrence. An increase in fatal drug 
poisonings and drug findings does not necessarily implicate rising drug abuse, 
because many of the illegally used drugs are also widely used as legal, prescribed 
medications. Studies III and IV combine toxicology laboratory results and 
individually collected information from each death certificate to estimate the 
proportion of drug abuse. In Finland, where about 13% of all deaths undergo 
toxicological analysis annually, postmortem data can provide estimates of problem 
drug use among the entire population. Postmortem toxicology among the young 
deceased is common in Finland and involves 60 to 70% of them [92]. Studies III 
and IV revealed the minimum number of opioid- and gabapentinoid-abuser cases. 
The proportion of opioid use other than abuse was, however, impossible to estimate, 
because the elderly, more often on prescribed and properly used medication, 
undergo toxicological cause-of-death investigation less often than do young abusers.  
Buprenorphine-naloxone, in addition to buprenorphine, involves wide abuse. 
This thesis study reveals that BNX may, in accidental poisonings, be fatal even more 
often than buprenorphine (VI). Other key findings were the high abuse proportion of 
pregabalin and tramadol, and the high prevalence of opioids in pregabalin deaths 
(IV).  The abuse potential of pregabalin and tramadol has been noticed in another 
Finnish study, as well [194]. In Study III, tramadol differed somewhat from other 
medicinal opioids. Its abuse percentage was only 29%, compared to abuse 
proportions for buprenorphine and methadone of over 80% (III). Tramadol use in 
Finland is, however, quite common, and of all the abuse cases, tramadol accounted 
for 20%, being in number of cases the second most abused opioid (III). Tramadol 
seizures by Finnish Customs have increased markedly [124], which would likely 
indicate increasing tramadol abuse. Deaths involving tramadol abuse usually involve 
polydrug use [195], consistent with the findings in this thesis. Tramadol poisonings 
included more benzodiazepines than did other tramadol-related deaths (I), and 
tramadol abuse included more concomitant opioids than did other tramadol deaths 
(III). Potential pharmacokinetic and pharmacodynamic interactions between 
tramadol and other drugs may enhance these drugs’ toxicity and lead to a fatal 
outcome.  
Findings concerning the abuse liability of tramadol are somewhat contradictory. 
When tramadol came onto the market, it was suggested to have little abuse potential 
[196-200], but other studies call it considerable [195,201,202]. Because of 
tramadol’s atypical character as an opioid and its effects on serotonin and 
noradrenalin reuptake besides its opioid activity, its abuse potential, dependency, 
and complications via opioid-receptor effects have been considered low, making it 
50 
 
recommendable as a safe drug compared to other opioids [196]. In animals, tramadol 
produces drug-seeking behavior [116], but the abuse potential of tramadol in 
animals has been less than that of typical opioids. In humans, its oral, but not 
parenteral, administration has produced opiate-like effects [199]. Because tramadol 
elicits only modestly positive subjective effects, it has been judged as only rarely 
useful as a highly desirable euphoriant [199]. One German expert committee has 
recently found a low potential for its misuse, abuse, or dependency [200]. Tramadol 
may well act as a less preferably abused drug compared to other opioids. Oral 
tramadol has, however, a reinforcing efficacy in prescription opioid abusers, leading 
to risk for abuse [202]. Among recreational-drug users, oral tramadol has abuse-
liability effects [201].  
Reasons for drug abuse include not only a search for euphoria. For most drug 
abusers, getting high is the primary initial motive, but as drug abuse continues,  the 
motive evolves into avoidance of withdrawal symptoms [203]. Besides getting high, 
motivations for non-medical prescription-drug abuse also include coping with stress, 
moderating other drugs’ effects, experimentation, and pain relief [203,204]. In this 
context, it seems obvious that tramadol also has marked abuse potential, although its 
effects were weaker than those of stronger opioids. Tramadol abuse is a health 
problem that needs more preventive action in Finland, as well.  
Weak opioids and gabapentinoids may not be the first-line drugs of abuse, but 
they are abused, for example, in boosting opioid effects. Opioids or gabapentinoids 
are not the drugs of choice for patients with drug addiction or a drug-abuse history. 
Gabapentinoids should be excluded from use for drug addicts and abusers with, for 
example, neuropathic pain resulting from limb amputations; other, less-addictive 
medications are available. Doctors should pay special attention to opioid and 
gabapentinoid prescriptions. One should carefully inspect for signs of injecting and 
signs of drug abuse. Doctors should receive training in avoiding those medicinal 
products that abusers prefer, and in minimizing the ever-present abuse risk when 
prescribing opioids. This training could include a choice between short- and long-
acting products, and the types of packages and products abusers especially prefer. 
For example, tramadol is available in short-acting capsules which are quite easy to 
open and dilute in water, when compared to slow-release hard tablets. Opioids and 
gabapentinoids should be prescribed in primary health care only for valid indications 
and short periods. For drug addicts, treatment against pain other than medications 
may be preferable [205].  
The cooperation of health care and forensic professionals is vital in identifying 
and implementing preventive strategies against drug abuse [206]. Medical 
practitioners should be cautious with drug prescriptions, and forensic pathologists 
should provide more consistent and detailed information on prescription drug use 
[206]. Investigation of deaths of suspected drug abusers and deaths suspected to 
relate to poisonings or to traumatic accidents should always include postmortem 
toxicology, which will ensure rather reliable estimates of drug-abuser deaths.  
Conclusions based on postmortem laboratory data are, however, far from 
complete, even were the rate of postmortem toxicology high. Determining whether a 
case involved drug abuse was based on referrals and death certificates issued by 
forensic pathologists, and then the relevant information may have been in some 
cases very scarce. Improvements for research purposes would include a more 
accurate patient history from forensic pathologists to be shown in referrals and death 
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certificates. In Study V, combining laboratory data on postmortem samples with 
samples from known drug users, along with proper background information, assisted 
in interpretation of laboratory analysis results; this helped to distinguish drug abuse 
from other use. New laboratory analytics also require attention: German researchers 
have created laboratory methods measuring disaccharides in urine samples to 
determine intravenous methadone or buprenorphine abuse [186,207]. Combining 
such laboratory analyses with regular drug toxicology data would surely improve 
postmortem abuse studies and more easily provide information on drug abuse than 
do studies based on combined register data. 
According to the Decree of the Ministry of Social Affairs and Health on 
Prescription of Medicines (1088/2010), special attention should be directed at 
prescription of medications with addiction potential [208]. Policy-makers should, 
however, notice that directions for safe prescriptions are insufficient to prevent drug 
abuse. Although directions for benzodiazepine prescribing already exist, prescription 
benzodiazepines are still widely abused. To prevent drug dependence, a doctor 
should monitor each patients’ drug use [208]. This monitoring could include 
questionnaires regarding medication benefit and harm, patient data from earlier 
treatment periods and from other treatment units, and urine drug screening [209]. 
Such screening should be more easily available and performed, even before 
suspicion of drug abuse arises. Gudin et al. suggest routine urine toxicology testing, 
including opioids, benzodiazepines and ethanol biomarkers, for all patients receiving 
opioid medication in pain management [210]. New, cost-efficient urine drug 
screening methods are already available, methods that allow simultaneous screening 
and confirmation both of conventional drugs of abuse and of new psychoactive 
substances. They show performance far beyond that of a conventional immunoassay 
[211]. Resources in primary health care must be sufficient for doctors to be able to 






The typical death of a Finnish opioid abuser is an accidental, delayed polydrug 
poisoning involving opioids, gabapentinoids, benzodiazepines, alcohol, or other 
psycholeptics. The victim is typically a male in his thirties. Compared to the period 
2000-2008, in 2010-2011, the frequency of concomitant alcohol and opioid findings 
for fatal opioid poisonings increased. During 2010-2011, concomitant opioids were 
associated with half the abuser cases involving opioids other than buprenorphine, 
and almost a quarter of the buprenorphine cases. Codeine and tramadol, in 
particular, were involved in polydrug use, with more additional benzodiazepines in 
poisonings than in other deaths, and in abuser cases, more concomitant opioids. 
Opioids played a significant role in pregabalin- and gabapentin-abuser deaths: 
almost all of these included opioids. 
In opioid poisoings, postmortem blood drug concentrations may be low, and they 
may alone be insufficient for determining cause of death; proper background 
information in addition to concentration data is necessary. Codeine, tramadol, 
pregabalin, and gabapentin concentrations among drug abusers in fatal poisonings 
were generally higher than their therapeutic upper limits. Median buprenorphine and 
methadone concentrations fell within their therapeutic ranges, rather similar between 
poisonings and other deaths, as well as between abusers and other users. For some 
opioids, concentrations of their metabolites or concentration ratios of the parent and 
metabolite may prove more useful than mere parent concentrations, although 
concentration ratios also overlap between poisonings and therapeutic cases. In 
buprenorphine poisonings, the norbuprenorphine/buprenorphine ratio was low. In 
codeine poisonings, the concentration ratio of codeine/morphine was high. Tramadol 
poisonings were associated with high concentrations of tramadol’s active metabolite 
O-desmethyltramadol.  
Abuser cases among all deceased opioid and gabapentinoid users, as well as fatal 
opioid poisonings, were concentrated in young to middle-aged men. Buprenorphine 
and methadone findings were most often associated with abuse. Pregabalin and 
tramadol, as well, appeared in a considerable proportion of abuse cases. The 
proportion of tramadol poisonings among all tramadol-related deaths in abuser cases 
from 2000-2008 increased during 2010-2011 by a third, and the proportions of 
fentanyl and oxycodone poisonings doubled. Fentanyl abuse was rather rare but 
seemed especially dangerous, because a great majority of the fentanyl-abuser deaths 
were accidental overdoses.  
Despite the opioid antagonist naloxone, parenteral BNX abuse was commonly 
related to fatal buprenorphine poisonings, proportionally even more than was the 
case with the abuse of buprenorphine. Buprenorphine and naloxone concentrations 
measured in urine can diagnose parenteral BNX abuse. Although naloxone was 
measurable also in sublingual BNX use, its concentration remained low. The urine 
naloxone/buprenorphine concentration ratio provided an abuse indicator for BNX, a 




Finland’s comprehensive, constantly enlarging postmortem toxicology database 
provides information for forensic medicine, public health, and clinical medicine. 
Finland’s high postmortem toxicology rate allows detection of drug poisonings and 
more accurate cause-of-death investigation. These data produce, moreover, 
prevalence data through drug findings and reveal emerging trends in both 
prescription-drug and illegal-drug use settings. Recognizing drug-abuse trends can 
enable appropriate drug regulation and enforcement that should have a positive 
impact on morbidity and mortality. Analytical laboratory methods for measuring 
drug concentrations as well as conclusions based on concentration data are 
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